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The mechanism by which certain DNA sequences are chosen to function as DNA 
replication origins, in metazoan genomes, is currently not understood. However, a 
comparison of the DNA loci identified as replicators so far points towards a role for DNA 
topology in this process.  DNA topoisomerases are the modulators of DNA topology 
inside the cell, their activity being essential in all living organisms, nevertheless, the 
involvement of topoisomerases in metazoan DNA replication is poorly characterized. In 
this study, the role of topological modulation of the origin DNA was investigated by 
mapping the interaction of human topoisomerase I and II with a human origin. The lamin 
B2 DNA replication origin, located on human chromosome 19, interacts with the DNA 
topoisomerases I and II in a cell cycle modulated fashion.  The topoisomerases interact in 
vivo with precise bonds ahead of the start sites of bidirectional replication, within the pre-
replicative complex region. Topoisomerase I introduces two single stranded cleavages, on 
the origin upper and lower strand respectively, in M, early G1 and at late G1 - G1/S 
border, with topoisomerase II introducing also two single stranded cleavages, on the 
origin upper and lower strand respectively, in M and middle of G1 phase of the cell cycle. 
At the origin, topoisomerase II interacts with Orc2p during the assembly of the pre-
replicative complex in the middle of G1 phase of the cell cycle. Furthermore, 
topoisomerase I interacts with Orc2p in late G1 - G1/S border as part of the origin 
initiation complex and inhibition of topoisomerase I activity abolishes origin firing. The 
two topoisomerases also compete for the same sites bound by the Orc2 protein, in 
different moments of the cell cycle.  In vitro, human recombinant DNA topoisomerase I 
is able to distinguish the same sites on origin DNA as the in vivo cleaved ones, with some 
additional cuts on the upper strand. In contrast, human recombinant DNA topoisomerase 
II, alone, cannot introduce the same precise origin cleavages, but as part of an in vitro 
origin specific multi-protein complex it can recognize and cut exactly the same sites as in 
vivo. Thus, the two topoisomerases are members of the replicative complexes with DNA 




1.1 DNA Topology and replication 
 
In both prokaryotic and eukaryotic organisms DNA replication is the process 
upon which the cell relies to duplicate its DNA and ensure that at each cell division both 
daughter cells contain exactly the same genetic information. A process which deals not 
only with the problem of faithfully copying the entire genome in a considerably short 
time but also with managing the chromosomes, long polymers which require a higher or 
lower degree of packaging at any given moment.  
When in 1953 James Watson and Francis Crick proposed their model for the 
structure of DNA in the Nature journal they had in fact guessed correctly the mechanism 
by which the double helix could be duplicated using the specificity of the base pairing. 
Melting the duplex allowed for semi-conservative DNA replication assuring that the two 
new DNA molecules were identical (Watson and Crick, 1953a). Nevertheless they also 
recognized a problem innate to this process: the DNA overwinding (Watson and Crick, 
1953b). If DNA had a straight zipper-like structure denaturing the duplex would be easy 
enough, instead its helical conformation means trying to separate the two strands will 
create torsional stress outside the unwound region. They proposed the so-called 
‘speedometer model’, where DNA molecules during replication can rotate around their 
axis much like a car speedometer. 
Soon afterwards it was the turn of Max Delbrück to make the correct speculation 
that, in order to remove the stress of overwinding, DNA could be transiently broken, 
allowed to rotate around its axis and religated (Delbrück, 1954). Still it was only in 1971 
that James Wang first described an enzyme which could catalyze this reaction, the 
Escherichia coli ω protein (later renamed topoisomerase I). 
Topoisomerases are enzymes which can relax or supercoil DNA, decatenate 
chromosomes and catenate or decatenate circular plasmid DNA. All these reactions 
involve a single or double stranded cleavage of the substrate with concomitant covalent 
crosslink of the enzyme to the DNA. This feature has made topoisomerases targets for an 
ever growing collection of antimicrobial and anti-cancer drugs, which inhibit the 
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religation step of the catalytic cycle of the enzyme. These therapeutic agents act by 
‘poisoning’ the enzyme, transforming it into a DNA-damaging agent due to the 
persistence of enzyme induced nicks or double stranded breaks. 
Today we know that topoisomerases are enzymes essential in any organism, 
which deal with the topological requirements of not only DNA replication, but also 
transcription, repair, recombination and many other processes. Nevertheless many of the 
functions of these enzymes are not well characterized. Although DNA topoisomerases are 
absolutely required for DNA replication, a detailed characterization of which enzymes 
are involved in different steps or an investigation of the possible functional overlap 
between the many types of topoisomerases found in the cell is still to be described. 
Another interesting question is whether other enzymes might be able to replace DNA 
topoisomerases during this process.  
The effectiveness of the aforementioned antimicrobial and anti-cancer drugs is 
thought to be replication-dependent: collision of a replication fork with a topoisomerase 
induced DNA break would generate a double stranded DNA break, a situation called 
‘replication run-off’, which in turn would give rise to illegitimate DNA recombination 
and ultimately apoptosis if the DNA damage is extensive. A better understanding of the 
topoisomerase function in DNA replication would also help in developing better 
topoisomerase poisons.  
Initiation of DNA replication is a complex process which requires the assembly of 
a large pre-replicative complex over a chromosomal region which will be used in S phase 
as an origin of DNA replication. The choice of DNA fragments which will function as 
replication origins is a poorly understood process. In metazoans, the few origins which 
have been characterized in detail exhibit no sequence similarity and, so far, no proteins 
have been discovered which bind specifically only to origin DNA. There are, however, a 
series of factors which seem to facilitate the ability of a region to function as an origin, 
like an open chromatin structure, bent DNA structures, gene promoters close-by, binding 
sites for sequence specific proteins or asymmetric AT-rich stretches. These clues hint at a 
role for DNA topology in establishing an origin of DNA replication. A particular DNA 
conformation could be the key to the high affinity binding of the first pre-replicative 
complex during G1. Furthermore, throughout the G1 phase of the cell cycle, the pre-
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replicative complex undergoes a dynamic re-organisation process while bound on the 
DNA. Since topoisomerases are able to alter the topology of a DNA region, they could 
play a determining role in origin specification and regulation. 
The present work concentrates on the role of human DNA topoisomerases I and II 
at a human origin of DNA replication: the lamin B2 origin. Currently the best 
characterized origin of DNA replication in humans, the lamin B2 offers a unique tool for 






1.2 Reconciling the structure of DNA with its biological functions. 
 
In order to understand how the cell deals with the complex process of faithful 
genome replication before mitosis, the way in which chromosomes are packed and 
maintained inside the nucleus should be considered. There is a huge discrepancy between 
the length of the chromosomes and the size of the nucleus and it is obvious that 
chromosomes are tightly packed inside the cell. Nevertheless, the possible need at any 
given moment for the production of a particular protein, in response to environmental or 
developmental cues (just to give one example of a process requiring chromosome 
decondensation), signifies the unpacking and transcription of a particular chromatin 
domain. Hence the need for a tightly regulated yet flexible DNA packing-unpacking 
regime inside the nucleus. DNA replication, transcription, recombination, mitosis and 
meiosis are all events which rely heavily on the ability of the cell to manage its genome. 
 
1.2.1 The double helix 
 
The genetic material inside all organisms is the deoxyribonucleic acid – DNA. It 
is a long double polymer made out of two chains of polynucleotides which run in an anti-
parallel sense. A nucleotide is composed of one of four possible heterocyclic bases linked 
to a sugar which, in turn, is linked to a phosphate group. The polymerization reaction 
involves the formation of a phosphodiester bond between two sugar groups, with the base 
as a side chain. Figure 1.2.1.1 illustrates the building blocks of DNA.  
The two polynucleotide chains are kept together by hydrogen bonds formed in 
between the heterocyclic bases, which are positioned, towards the inside of the DNA 
structure, roughly perpendicular on the backbone (the bases are stacked). Out of the four 
possible bases found in DNA: adenine, guanine, thymine and cytosine, the hydrogen 
bonding is possible only between an adenine and a thymine (2 hydrogen bonds per pair) 
or a guanine and a cytosine (three hydrogen bonds per pair). These normally weak 
hydrogen bond interactions give the strength of the polynucleotide-polynucleotide 
interaction by their sheer number. In fact, the longer the piece of DNA the harder it is to 
denature it, namely to physically detach one polynucleotide chain from its complement. 
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Because the base-base interaction in DNA is not random, the two polynucleotide 
polymers which bind each other are complimentary. 
     
Figure 1.2.1.1 - The 
four heterocyclic bases 
found in DNA and the 
hydrogen bonding 




The polynucleotide chain has also a polarity stemming from the fact that, when 
linking the nucleotide groups, two different positions are used to form the bond: the 3’ 
hydroxyl end of one sugar group with the phosphate found at the 5’ end of another sugar 
group. As mentioned previously, the DNA is formed of two polynucleotide chains (also 
called DNA strands) which are anti-parallel. Furthermore, this double stranded structure 
was shown to adopt a right-handed helical conformation. This allows for the formation of 
a hydrophobic core, formed of the hydrogen bonded bases, and a hydrophilic exterior 
composed of the backbone sugar-phosphate groups. This helical structure derives from 
the fact that the building blocks of DNA are asymmetric (four possible nucleotides based 
on the four possible heterocyclic bases) and, as a result, the stacking of the hydrogen 
bonded bases is slightly staggered.  
The overall conformation of the double helix depends not only on the sterical 
hindrance of the bonds within the molecule but also on the physical properties of the 
solvent. The classical DNA double helix structure proposed by Watson and Crick 
corresponds to B-form DNA which is thought to correspond to the majority of the 
cellular DNA. Nevertheless, two other types of DNA have also been described: the A-
form and the Z-form. In the B-form DNA, the helix is right-handed and the bases are 
stacked almost perpendicularly on the backbone. The helicity of the molecule is not 
uniform and the DNA has a major groove (wide and deep) and a minor groove (narrow 
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and deep). The number of base-pairs per helical turn (also called the DNA helical repeat) 
was determined to be 10.5 and the diameter of the double helix was measured to be 20Å 
(Feughelman et al., 1955). 
In A-form DNA the helix is still right-handed but the bases are tilted to form 
angles much bigger or smaller than 90° with the sugar-phosphate backbone. This tilt 
results from a different conformation of the furanose ring of the sugar. The number of 
base-pairs per helical turn is 11 and the diameter of the double helix is 26Å. As a result 
the major groove is narrow and deep, while the minor groove is wide and shallow 
(Feughelman et al., 1955). 
In Z-form DNA the helix is, surprisingly, left-handed and the bases are 
alternatively perpendicular and tilted as in B-form and A-form DNA. This alternating 
pattern corresponds to the alternating conformation of the sugar, which is either C2’-endo 
(B-form) or C3’-endo (A-form). As a result the sugar-phosphate backbone has a 
zigzagged pattern, the major groove is completely flat while the minor groove is narrow 
and deep. The number of base-pairs per helical turn is 12 but the diameter of the double 
helix is much smaller, 18Å. This particular form of DNA is typical of sequences 
composed of alternating GC tracts and is conditioned by the solvent composition (high-
salt apparently promotes the formation of Z-form DNA) (Herbert and Rich, 1996). 
The existence of A-form and Z-form DNA in vivo is still questioned but there is 
some evidence that at least in particular situations (e.g. gene activation, supercoiling) 
DNA may adopt a different conformation (Fairall et al., 1989, Singleton et al., 1982 and 
Liu et al., 2001) . 
Being a flexible polymer DNA can be forced into a more compact or looser 
double helix, this property referring to the degree of supercoiling of a DNA molecule. In 
its relaxed state the B-form double helix has a helical repeat of 10.5 nucleotides. If a 
DNA molecule has this helical repeat for all its helices it is considered to be in its relaxed 
state (not supercoiled). If parts of the molecule or the whole of it has a higher or lower 
number of base-pairs per helical turn than this value, it is considered to be, respectively, 
negatively or positively supercoiled. Negative supercoiling leads eventually to the 
separation of the two DNA strands, while positive supercoiling tightens the helix and 
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ultimately makes it coil upon itself. This feature of DNA obviously stems from its helical 
nature and plays a central role in many aspects of DNA metabolism.  
For a circular DNA molecule, or a linear one whose ends cannot rotate freely, a 
measure of the degree of DNA supercoiling can be obtained from the linking number. 
This value represents the number of double-helical turns the DNA molecule contains and 
it describes the topology of DNA. Two DNA molecules which differ only in the linking 
number are known as topological isomers or topoisomers. Therefore a change in DNA 
supercoiling implies a change in DNA topology. 
All the characteristics here described for the double helix refer to biochemical and 
biophysical studies of DNA alone in different solutions. This is a good starting point for 
understanding the nature of DNA but is insufficient for appreciating its behavior in 
complex situations, as one would expect to find in vivo. Many factors affect the DNA 
conformation inside the cell, from the ionic strength, to the availability of different 
cations, to the interaction of the DNA with proteins. This is why it is important to 
understand the properties of the DNA molecule inside the living organism. 
 
1.2.2 Nuclear architecture, chromatin and the scaffold.  
 
In both prokaryotes and eukaryotes the chromosomes are packed within a much 
smaller space than the length of the extended DNA molecules. Just to give one example 
in eukaryotes the estimated packing ratio inside the interphase nucleus is that of 250 fold, 
while during mitosis it reaches 10000 fold. In spite of the almost one hundred years of 
research into how DNA is packed in vivo, the exact process by which this tremendous 
chromosome condensation is achieved remains poorly understood.  
There is a striking difference between the way eukaryotes and prokaryotes deal 
with chromosomes inside the cell. Prokaryotic organisms often contain just one 
chromosome, for the most circular, which is much smaller in length compared to the 
eukaryotic counterpart. Inside the cell there is no specific membrane-bound structure (e.g. 
the nucleus in eukaryotes) which separates the genome from the rest of the cell, instead 
the chromosome can be detected by electron microscopy as an irregular dispersed 
structure called the nucleoid. There is evidence that proteins are associated with these 
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chromosomes for packing purposes but their exact role is not known. Still, the E.coli 
chromosome (4.6kb of circular DNA) is compacted roughly 1000 fold in the cell. 
Eukaryotes on the other hand, posses an array of chromosomes which are located 
inside a specific organelle, the nucleus. They also have more than one chromosomal set at 
least at one stage during their life cycle. The chromosomes are found in a packed state 
generally referred to as ‘chromatin’ and this term comprises all the different DNA 
packing stages from the least condensed one during interphase to the structures seen in 
mitosis. Chromatin inside the nucleus is usually of two types: euchromatin, a low-
packing actively transcribed form, and heterochromatin, tightly packed regions which 
associate with a gene repression status. 
The structure of chromatin is characterized well at its basic level of assembly but 
the mechanism concerning higher levels of packing remains strictly hypothetical. 
Eukaryotes have evolved a subset of nuclear proteins which associate specifically with 
DNA, called histones. These are small, highly basic proteins (rich in lysine and arginine) 
which are extremely well conserved across the whole eukaryotic domain. The histone 
family contains five members: H1, H2A, H2B, H3 and H4.  
Histones H2A, H2B, H3 and H4 form an octameric subunit comprising 4 
heterodimers: two H2A- H2B and two H3-H4. The DNA is wrapped 1.7 times around 
this octamer in a left-handed manner and the resulting structure is called a nucleosome, 
the smallest structural subunit of chromatin. Each histone heterodimer binds 30bp of 
DNA and a nucleosome was found to contain 147bp of DNA. The nucleosome is a stable 
structure, with the ability to self assemble in vitro. The fifth histone, H1 binds on the 
outside of the nucleosome, possibly close to the entry/exit point of the DNA double 
strand, and has a stabilizing role for the DNA-histone octamer interaction. Together the 
nucleosome and histone H1 bind 167bp of DNA and the resulting structure is called a 
chromatosome.  
The overall reduction in DNA length through the assembly of nucleosomes is 
only of 7 fold and therefore highly insufficient for the requirements of the cell. A 
second step in DNA packaging involves the assembly of the 30nm fiber. Chromatosomes 
can be assembled onto DNA with a spacing of 0-80bp (this represents the length of the 
‘linker DNA’). In turn this structure can be further assembled into a solenoid by 
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compacting the chromatosomes into a tight left handed helix with a diameter of 30nm. 
The exact way in which this compaction is achieved is still a matter of debate with 
several models proposed, nevertheless all models agree on a tight chromatosome 
assembly with the linker DNA completely folded inside the solenoid as a way of 
shortening the double helix.  
It is thought that the majority of the DNA in interphase is in the solenoid state, 
with different regions being less packed. Actively transcribed regions still have 
nucleosomes but histone H1 is lost and higher order condensation is usually absent. In 
general, chromatin is a dynamic and highly regulated structure, with histone 
modifications altering the nucleosome stability and performing the so called ‘chromatin 
remodeling’.  
 Higher levels of chromatin condensation beyond the 30nm fiber are currently just 
at the speculation step with a range of scientific data pointing towards the assembly of the 
solenoid into a set of DNA loops attached to a nuclear scaffold. The chromosome size in 
mitosis makes it obvious that higher degrees of packing must exist and considering that 
the assembly of the basic unit of chromatin, the nucleosome, is based on protein-DNA 
interactions, it is logical to assume that further chromatin compaction is also protein 
dependent.  
In a critical experiment it was shown that if the nuclei are isolated, histones are 
removed with 2M NaCl (along with the majority of the proteins) and DNA degradation is 
inhibited by inactivating nucleases, the DNA can be seen by electron microscopy as a 
halo surrounding the remnants of the nucleus (nucleoid). Surprisingly if this DNA 
preparation is treated with ethidium bromide, an intercalating dye which unwinds the 
double helix by inserting itself in between the bases, the DNA filaments become less 
diffused (McCready et al., 1979). This apparent paradox means that the local unwinding 
caused by the dye has in turn induced DNA supercoiling. This outcome is typical of 
circular DNA and is only possible in a linear DNA molecule if the ends are unable to 
freely rotate. Thus came the hypothesis that DNA inside the nucleus is organized into 
loops which are anchored to a nuclear structure.  
Another experiment involving mitotic chromosomes reached the same conclusion 
using a completely different approach: using electron microscopy, metaphase 
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chromosomes depleted of histones show an electron-dense core, termed the nuclear 
scaffold, to which DNA loops are attached (Paulson and Laemmli, 1977). These loops are 
70m in size and probably correspond to the next chromatin compaction level after the 
30nm fiber. The nature of the nuclear structure which tethers the DNA loops (also called 
scaffold or matrix) remains an opened question. Problems stemming from the lack of 
methods for the isolation a ‘bona fide’ nuclear scaffold, with the high probability of many 
artifacts being present as a result of protein aggregation, made it impossible to progress 
further in this direction. If the existence of DNA loops is generally accepted, the nuclear 
structure isolating these loops is an incognita (Turner, 2001).  
However this long struggle to characterize the nuclear scaffold has allowed the 
discovery of a series of important features of the nuclear architecture like the nuclear 
lamina. This proteinaceous network is formed of two families: A-type lamins (e.g. lamin 
A and C) and B-type lamins (e.g. lamin B). These proteins form a meshwork at the inner 
surface of the nuclear envelope and possibly also throughout the nucleoplasm (Hozak et 
al., 1995). The lamin family of proteins has not yet been found in lower eukaryotes or in 
plants but is conserved in metazoans. The role of the lamins is not well understood but 
protein-protein interactions show that they might bridge the gap between the nuclear 
envelope and chromatin binding proteins and could also function in mechanotransduction 
signaling inside the cell. Nevertheless, the nuclear lamina is unlikely to correspond to the 
nuclear scaffold since the high salt extraction method used to isolate chromosome loops 
removes the nucleoplasm lamin network.  
In parallel, studies of scaffold proteins associated with metaphase chromosomes 
have led to the discovery of another important family of proteins, the SMC (Stability of 
Minichromosomes) family. The SMCs are proteins required for the correct chromosome 
condensation and segregation in yeast and homologues have been found in higher 
eukaryotes as well. They associate with chromosomes during mitosis and their similarity 
to motor proteins (e.g. kinesin) points towards a role in chromosome movement. Another 
component of the metaphase chromosome scaffold is topoisomerase II (Gasser et al., 
1986). This enzyme is essential in eukaryotes due to its crucial role in chromosome 
decatenation and mitosis (Nitiss, 1998). If topoisomerase II is thought to be always 
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present in the nuclear scaffold, the SMC proteins are more likely to be associated with 
chromosome during mitosis only. 
 Out of all the proteins studied so far, topoisomerase II is probably the most likely 
‘bona fide’ scaffold protein. It is considered the most abundant protein inside the scaffold 
and many searches of DNA scaffold/matrix attachment sites (SAR/MAR) were based on 
the affinity of topoisomerase II towards a piece of DNA (Razin et al., 1991). Yet, as an 
exact description of the scaffold (or safe method to isolate it) does not currently exist, all 
these data should be treated with a fair amount of skepticism.  
 However, if DNA loops exist, then they must be somehow kept in place, attached 
to a fairly rigid structure. If so, certain DNA regions will be indeed SARs/MARs. 
Whether these DNA regions are bound due to their sequence or at random, by simple 
charge interactions (as in the case of the histones), is not yet clear. The electron 
microscopy experiments described previously for both interphase and metaphase 
chromosomes suggest a very strong attachment of SARs/MARs to the scaffold, so why 
are these interactions so hard to reproduce in vitro?  
 A final piece of evidence in favor of DNA loops comes from chromosome 
staining techniques. The classic Giemsa chromosome staining, used for many years in 
karyotyping, reveals a species and chromosome-specific reproducible banding pattern of 
alternating dark bands (also called G-bands) and light bands. The opposite staining 
pattern (G-bands unstained and the light bands darkly stained) can be obtained by a 
reverse staining procedure (the dark colored bands resulting in this case are called R-
bands). The crucial feature of these bands is that they can be obtained with minimum 
manipulation of the cells (as opposed to the lengthy and delicate procedures used to 
obtain the chromosomes and deplete histones) and that they seem to be reproducible with 
different staining techniques in both mitotic and meiotic chromosomes. Use of different 
dyes specific for AT-rich or GC-rich DNA has shown that G-bands correspond to 
chromatin domains containing very AT-rich regions, while R-bands correspond to 
chromatin domains containing very GC-rich regions. Based on the observation that G-
bands have somewhat of a coiled structure in less condensed chromosomes, a new model 
was proposed for the organisation of DNA loops. Since AT-rich regions were found to be 
preferentially associated to nuclear scaffold preparations, the coiled structure of G-bands 
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would be a consequence of the high-density SARs/MARs nature of this DNA. Further 
condensation of these small loops would cause supercoiling. Instead the R-bands, GC-
rich, would contain a much smaller number of SARs/MARs, resulting in much bigger 
DNA loops (Saitoh and Laemmli, 1994).  
 If DNA packing is an essential requirement for managing the eukaryotic 
chromosome complement, tight regulation of nuclear compartments is also necessary for 
efficient nuclear function. The organization of the interphase nucleus is not well 
characterized yet but some key features have emerged. 
The most important nuclear compartment, the nucleolus, is the place of ribosomal 
DNA (rDNA) transcription and ribosome assembly. It contains a fibrillar centre, where 
both active and inactive rDNA genes are found, surrounded by a dense fibrillar 
component specialized in processing and assembly of rDNA, in turn surrounded by a 
granular component responsible for ribosome maturation (Shaw and Jordan, 1995). In 
humans five different pairs of chromosomes contain rDNA genes and all these loci 
cluster inside nucleoli.  
Clustering seems to be a common mechanism by which different biological 
functions are regulated inside the nucleus. DNA loci used in the same process tend to 
cluster and form large foci. It is the case of active DNA replication (Nakamura et al., 
1986). In mammalians centromeric heterochromatin tends to cluster in pericentric foci 
(Haaf and Schmid, 1991). Homology-dependent gene silencing which involves the down-
regulation of a gene due to the presence of a transgene might function via clustering and 
physical interaction of the two genes (Fransz et al., 2002). DNA insulator elements which 
can block the effect of an enhancer or protect from a silencer are also thought to function 
by tethering a chromatin domain (possibly a DNA loop) to a particular structure (e.g. 
nuclear pore) (Blanton et al., 2003).  
In addition, whole chromosomes seem to occupy individual territories inside the 
nucleus and rarely a chromosome will invade the territory of another in interphase. This 
is not a species specific organization, instead is more likely to reflect chromosome 
decondensation after mitosis. Still, chromosome movement is restricted inside the cell. 
One obvious reason is the sheer size of the DNA molecule. Quantitation of DNA 
movement in yeast has shown a difference between heterochromatic and euchromatic 
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loci, with the active chromatin domains moving more, presumably due to enzymatic 
events (Heun et al., 2001).  
 
1.2.3 DNA structure and biological processes. 
 
As mentioned in Section 2.1, supercoiling is a very important DNA feature and all 
nuclear processes involving DNA manipulations have to overcome the consequences 
arising from the helical nature of DNA. The chromosome is highly packed inside the cell 
and due to these topological constraints any form of supercoiling will affect heavily a 
chromatin domain (isolated by an anchored chromatin loop) without the possibility of 
distributing the strain over a much longer DNA molecule. Hence the need for 
topoisomerases, enzymes specialized in altering the topological state of DNA. 
 The chromatin organization inside the nucleus endows DNA with negative 
supercoiling. During nucleosome assembly positive supercoiling is accumulated on the 
DNA and is released by the action of topoisomerases. As a result when the nucleosome 
disassembles the DNA will be left negatively supercoiled. This ‘stored’ negative 
supercoiling can be used for different biological processes like DNA transcription and 
replication. 
DNA replication initiation requires the formation of a bubble at the origin. This is 
obviously a process which requires a large amount of negative supercoiling to be 
introduced in the DNA in order to obtain the separation of the two strands, with resulting 
accumulation of positive supercoiling on both sides of the origin. Once the replication 
fork has been assembled and DNA synthesis has started the fork movement along the 
DNA will continue to unwind the two parental strands and even more positive 
supercoiling will accumulate ahead of the fork.  
If the replication fork complex is able to rotate around the DNA axis (not a likely 
possibility due to the sheer size of the replisome), the positive supercoiling will be 
distributed both ahead and behind the fork. If this positive supercoiling is not removed 
the DNA will begin to coil upon itself much like an over-twisted rope. At the point of 
termination of DNA replication where two replication forks converge, due to the 
accumulated positive supercoiling, the two daughter molecules will be intertwines, i.e. 
 19 
catenates are formed. Figures 1.2.3.1 and 1.2.3.2 illustrate the type of topological 
constraints encountered during DNA replication. 
Nonetheless, all these considerations about DNA topology during replication are 
just logical assumptions, what truly happens inside the cell and how the various in vivo 
protein-DNA interactions help or complicate topological problems is unknown.   
DNA transcription is another process which shares a few of the topological 
difficulties of DNA replication. The first step in transcription is also the separation of the 
two DNA strands in order to allow access of RNA polymerase to its template with 
resulting positive supercoiling in the surrounding region. Furthermore during active 
transcription it has been shown that the RNA polymerase (often coupled with ribosomes) 
does not rotate around the DNA axis and as a result positive supercoiling accumulates 
ahead of the enzyme, while negative supercoiling will build behind it (Figueroua and 
Bossi, 1988 and Tsao et al., 1989).  
  
 
    
 
 
Figure 1.2.3.1 - Replication 
elongation creates an 
accumulation of positive 
supercoiling ahead of the 
replication fork (a). If the fork 
complex can rotate around the 
DNA axis the positive 
supercoiling will be distributed 
both ahead and behind the fork, 
with resulting formation of pre-
catenates in the newly replicated 




Figure 1.2.3.2 - Replication termination 
is the point were two replication forks 
converge. The positive supercoiling 
resulting from the advancement of the 
two forks results in catenated DNA (c) 
(taken from Wang, 2002). 
 
1.3 DNA topoisomerases are modulators of DNA topology. 
 
1.3.1 Classification of DNA topoisomerases. 
 
In the cell, the only enzymes capable of modifying the degree of supercoiling of 
DNA (the so-called “linking number” of a DNA molecule) are the DNA topoisomerases. 
All topoisomerases identified so far regulate the degree of supercoiling of DNA via 
cleavage and formation of a transient covalent phosphor-tyrosine enzyme/DNA adduct. 
Moreover a particular subset of topoisomerases can also catenate/decatenate knot/unknot 
plasmid DNA. The catalytic cycle of DNA topoisomerases involves 4 steps:  
1. binding of the DNA substrate. 
2. cleavage of the DNA with concerted covalent attachment of the enzyme to the 3’ 
or 5’ DNA end via a nucleophilic attach of an enzyme tyrosine residue on a DNA 
phosphate. 
3. rotation and/or strand passage of the substrate in order to remove/introduce 
positive or negative supercoiling or catenate/decatenate, knot/unknot DNA 
molecules. 
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4. religation of the gap via a reversal of the transesterification reaction and release of 
the DNA substrate. 
An example of a topoisomerase cleavage reaction is given in Figure 1.3.1.1. 
Under physiological conditions the cleavage, rotation and religation are extremely quick 
and the covalent enzyme-DNA complex (also called the “cleavable complex”) is only a 
short lived intermediate. Nevertheless under specific conditions the equilibrium of the 
cleavage reaction can be shifted towards the cleavable complex state and the enzyme can 
be physically trapped on the DNA. Due to this particular property, the topoisomerases 
have long been recognized as potential DNA damaging agents and they are targets for a 






Figure 1.3.1.1 - 
Eukaryotic topoisomerase 
I is a type IB enzyme and 
becomes covalently 
attached to the 3’ end of 
its DNA substrate during 
the catalytic cycle.
Topoisomerases are usually specialized in one particular topological reaction (e.g. 
removing positive supercoiling as opposed to introducing it) and as a result it is common 
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to find more than one type of enzyme in each organism. At least one gene coding for a 
DNA topoisomerase has been identified in all organisms studied and it is generally 
assumed that topoisomerases are essential enzymes for cell growth due to their unique 
DNA decatenation activity (Champoux, 2001 and Wang, 2002). Based on the type of 
DNA cut they introduce, topoisomerases can fall into two classes: type I or type II. Type 
I enzymes can bind single or double stranded DNA and introduce single-stranded nicks, 
while type II cleave both DNA strands of a double helix. Further division within type I 
and type II into subtype A and subtype B is based on structural and catalytical properties. 
Table 3.1.1 illustrates the topoisomerase classification and enzyme properties.  
 
Table 3.1.1 The topoisomerase classification. 
Domain of life Type Structure Notes 
Topoisomerase Class IA  
The enzyme cleaves just one strand of the DNA substrate with concerted covalent attachment to 
the 5’ end of the cut. The DNA substrate is always negatively supercoiled with the enzyme 
requiring an exposed single-stranded region for catalytical activity. The relaxation reaction does 
not go to completion (i.e. the DNA will still be negatively supercoiled at the end of the reaction). 
The enzyme is also able to catenate/decatenate and knot/unknot single stranded DNA circles or 




Reverse DNA gyrase Monomer 
Reverse gyrase is the only enzyme 
capable of introducing positive 
supercoiling into its DNA 
substrate. All archaeal 
hyperthermophiles studied so far 
seem to have an active reverse 
gyrase, most probably important 
in neutralizing the effects of 
growth at high temperature. 
Topoisomerase III Monomer 
Relative sequence homology to 
the bacterial topo III. Found in 
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few organisms so far. 
Bacteria 
Topoisomerase I Monomer 
Seems to be present in all bacterial 
genomes fully sequenced so far. 
Topoisomerase III Monomer 
Some bacteria lack this type of 
enzyme. 
Topoisomerase IIIβ Monomer 
Identified only in Bacillus cereus, 
has distinct featured from all other 
type IA enzymes. 
Reverse DNA gyrase 
Monomer 
This enzyme has only been 
reported in hyperthermophilic 
bacteria. 
Heterodimer 
The only reverse gyrase with a 
heterodimeric structure was 












Saccharomyces cerevisiae topo III 
is dispensable for cell growth 
while Schizosaccharomyces 
pombe topo III is essential. 
Flies 
Topoisomerase IIIα Monomer 
Essential during development in 
Drosophila melanogaster. 
Topoisomerase IIIβ Monomer Not essential in D. melanogaster. 
Plants None reported so far.   
Mammals 
Topoisomerase IIIα Monomer 
Essential for embryogenesis in 
Mus musculus. 
Topoisomerase IIIβ Monomer Not essential in M. musculus. 
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Topoisomerase Class IB 
The enzyme cleaves just one strand of the DNA substrate with concerted covalent attachment to 
the 3’ end of the cut. The enzyme can relax positively or negatively supercoiled DNA substrates 
and the relaxation reaction goes to completion (i.e. the DNA will be in a relaxed state at the end 
of the reaction). The catalytical activity is not dependent on metal ions. 
Archaea None reported so far.   
Bacteria Topoisomerase V Monomer 
Present only in Methanopyrus 
kandleri and structurally distinct 












Not essential for growth. 
Flies Topoisomerase I Monomer Essential in D. melanogaster. 
Plants Topoisomerase I Monomer 
Essential in Arabidopsis thaliana. 
The Pisum sativum enzyme also 
exhibits reverse gyrase activity. 
Mammals Topoisomerase I Monomer Essential in M. musculus. 
Topoisomerase Class IIA 
The enzyme cleaves both strands of the DNA substrate (with a 4bp stagger) with concerted 
covalent attachment to the two 5’ ends of the cut. The enzyme has the ability to bind and pass 
another DNA double stranded region or molecule through the gap resulting from the DNA 
cleavage. This process results in DNA relaxation, knotting/unknotting or catenation/decatenation 
events. The catalytical activity is dependent on Mg
2+
 ions and ATP. However, it should be noted 
that different members of this class have very different efficiencies for relaxation, 
knotting/unknotting or catenation/decatenation reactions.  
Archaea DNA gyrase Heterotetramer 
Not very common in 
archaebacteria. 
Bacteria 
DNA gyrase Heterotetramer 
Found in all bacteria studied so 
far. 













Essential for growth. 
Flies Topoisomerase II Homodimer Essential in D. melanogaster. 
Plants Topoisomerase II Homodimer  
Mammals 
Topoisomerase IIα Homodimer 
In M. musculus essential for early 
embryogenesis.  
Topoisomerase IIβ Homodimer 
In M. musculus essential for late 
embryogenesis. 
Topoisomerase Class IIB 
The only member of this class of topoisomerases, topoisomerase VI, has the same catalytical 
properties of class IIA enzymes but shows very little sequence similarity with them. Topo VI is 
a A2B2 heterotetramer and the A subunit is homologous to the yeast Spo11 protein involved in 
meiotic recombination.  
Archaea Topoisomerase VI Heterotetramer 
Found in all archaebacteria studies 
so far. 






None reported so far. 
  
Flies None reported so far.   
Plants Topoisomerase VI Heterotetramer 
Essential for endoreduplication in 
A. thaliana. 
Mammals None reported so far.   
 
 
As mentioned before DNA topoisomerases are encoded in the genome of every 
genetic organism. Because topoisomerases participate in every aspect of DNA 
metabolism it is not surprising that during evolution they have acquired specialization for 
a particular topological reaction. At the same time prokaryotic and eukaryotic 
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topoisomerases seem to have evolved divergently and their characteristics show less 
similarities between these two taxonomical domains than expected.  
In prokaryotes the first topoisomerase discovered was the E.coli ω protein, now 
known as topoisomerase I (Wang, 1971). This is a 97 kDa monomer which exhibits a 
type IA catalytical reaction. The eukaryotic topoisomerase I (which has a reasonably 
conserved sequence from yeast to man) is a ~100 kDa monomer with a type IB catalysis. 
It should be noted that these enzymes were both called topoisomerase I assuming that 
they were orthologs and performed the same function within the cell. Nevertheless they 
have been shown not only to have no structural or sequence similarities but also to differ 
in the range of topological actions they can perform. Just to give an example eukaryotic 
topo I can relax both positive and negative supercoiling while E.coli topo I cannot relax 
positive supercoils.  
Type I topoisomerases act as monomers, contain only one catalytic tyrosine 
residues (as they introduce single stranded breaks) and do not normally require an energy 
cofactor (i.e. ATP). Type IA enzymes can relax only negative supercoils, require a 
single-stranded stretch in the DNA substrate, become covalently attached to the 5’ end of 
the DNA cut and cannot function in the absence of Mg
2+
 ions. Members of this class 
include prokaryotic topoisomerase I, prokaryotic and eukaryotic topoisomerase III and 
prokaryotic reverse gyrase. Apart from removing negative supercoiling, type IA enzymes 
can also perform knotting/unknotting and catenation/decatenation reactions. James Wang 
has postulated in his latest review about topoisomerases that “the minimal requirement 
for DNA topoisomerases in living organisms is probably one type IA and one type II 
enzyme” (Wang, 2002).  
E.coli topo I is efficient in removing negative supercoils but inefficient as a DNA 
decatenase. It plays a critical role in maintaining the optimum DNA supercoiling for all 
cellular functions and its role is particularly important during transcription (Drolet et al., 
1995). A topo I enzyme seems to be present in all bacteria investigated so far, however 
this enzyme is absent from archaebacteria (Champoux, 2001). E.coli topo III is related to 
the E.coli topo I and able to perform the same relaxation reaction in the presence of 
negative supercoiling. Nonetheless, it requires that the DNA substrate should be 
hypernegatively supercoiled and it is much more efficient in catenation/decatenation 
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reactions than topo I (DiGate and Marians, 1988 and Hiasa et al., 1994). Topo III is 
thought to be involved in the elongation and termination/decatenation events of DNA 
replication even though these roles would overlap with those of the E.coli type II 
topoisomerases (Hiasa and Marians, 1994 (b) and Hiasa et al., 1994). More evidence for 
this apparent functional redundancy comes from the fact that a number of other bacteria 
lack a topo III homologue (Champoux, 2001).  
Interestingly, in the bacterium Bacillus cereus two topo III enzymes have been 
identified, designated topo IIIα and topo IIIβ (Li et al., 2006). The B.cereus topo IIIα has 
the same catalytical properties as the E.coli topo III, while topo IIIβ can only partially 
relax negative supercoils and lacks decatenase activity. Furthermore, topo IIIβ cannot 
compensate for the lack of E.coli topo III in vivo (Li et al., 2006). The B.cereus topo IIIβ 
seems to be distinct from all other type IA topoisomerases and it remains to be seen if it 
performs an essential function in vivo.  
An archaeal topo III enzyme, related to the bacterial topo III, has also been 
reported for the hyperthermophilic archaeon Sulfolobus solfataricus (Dai et al., 2003).  
Eukaryotic topoisomerases III have been described in yeast, Drosophila, mouse 
and humans (Wallis et al., 1989, Wilson et al., 2000, Seki et al., 1998 and Hanai et al., 
1996). They have all the main features of the bacterial topo III, they can relax only 
negative supercoiling, need a single stranded stretch of DNA and Mg
2+
 ions in order to 
function. Even though Saccharomyces cerevisiae topo III is not absolutely required for 
cell growth, mutants for the gene exhibit slow growth, increased mitotic recombination 
and a defect in meiosis resulting in failed sporulation (Gangloff et al., 1999). Instead, 
deletion of the topo III enzyme is lethal in the yeast Schizosaccharomyces pombe and its 
presence is essential for accurate nuclear division (Maftahi et al., 1999 and Goodwin et 
al., 1999). Higher eukaryotes have two topo III isoforms:  and . In Drosophila topo 
III is essential during development, while topo III appears to be dispensable for 
viability in spite of having a peak of expression during the first 6h of embryogenesis 
(Wilson et al., 2000 and Plank et al., 2005). Knockout mice for topo III die early during 
embryogenesis, while topo III knockouts have a reduced life-span (Li and Wang, 1998 
and Kwan and Wang, 2001). Topo III seems to interact with DNA helicases of the RecQ 
family at least in yeast and humans and possibly functions in the same processes which 
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require these helicases (Bennett et al., 2000, Wu et al., 2000 and Shimamoto et al., 2000). 
Topo III together with BLM, Bloom’s syndrome helicase, seem to be involved in sister 
chromatid dissolution in mitosis (Seki et al., 2006). Interestingly, E.coli topo III also 
interacts with E.coli RecQ helicase (Harmon et al., 1999). 
Reverse gyrase is an enzyme found only in hyperthermophilic organisms 
including archaea and eubacteria and is the only type IA enzyme which requires ATP as a 
cofactor. The role of reverse gyrase is that of introducing positive supercoiling in a DNA 
substrate (Declais et al., 2001). Considering the special type of environment in which 
hyperthermophilic organisms grow in, it has been postulated that this enzyme helps 
protect the genome from the DNA denaturing effect of the extreme temperature 
(Charbonnier and Forterre, 1994). 
It is worth mentioning that genes coding for type IA topoisomerases were also 
found in several plasmids from Gram-positive and Gram-negative bacteria (Champoux, 
2001). Interestingly in one case it has been reported that initiation of plasmid replication 
by DNA polymerase I creates a substrate specific for a plasmid encoded topoisomerase 
(Bidnenko et al., 1998).  
If type IA enzymes are found in every organism, type IB are typical of eukaryotes 
with just one exception, topoisomerase V, which is present in a hyperthermophilic 
bacterium, Methanopyrus kandleri. 
Type IB topoisomerases can relax both positive and negative supercoiling, 
become covalently attached to the 3’ end of the DNA cut and do not require any type of 
metal ion or energy cofactor (Pommier et al., 1998). Their action is inhibited by single-
stranded DNA in contrast to type IA enzymes (Been and Champoux, 1984). In contrast to 
type IA enzymes, they are not capable of catenation/decatenation or knotting/unknotting 
reactions. Eukaryotic topoisomerase I, the vaccinia virus topoisomerase and 
Methanopyrus kandleri topoisomerase V are type IB enzymes.  
A topo I has been reported in all eukaryotic model genetic organisms including 
yeasts, Caenorhabditis elegans, Drosophila melanogaster, Xenopus laevis, wheat germ, 
mouse and human (Goto and Wang, 1985, Uemura et al., 1987a, Kim et al., 1996, Hsieh 
et al 1992, Pandit et al., 1996, Dynan et al., 1981, Koiwai et al., 1993 and Kunze et al., 
1989). In the yeasts S.cerevisiae and S.pombe topo I is not essential for growth, while in 
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higher eukaryotes, like Drosophila and mouse, absence of this enzyme is lethal (Thrash 
et al., 1984, Uemura and Yanagida, 1984, Lee et al., 1993 and Morham et al., 1996). 
Topo I is involved in many aspects of DNA metabolism including DNA replication, 
transcription, damage repair and possibly chromosome condensation in mitosis (Pommier 
et al., 1998). Along with the nuclear topoisomerase I, a mitochondrial topo I was 
identified in Xenopus, calf thymus and humans (Brun et al., 1981, Lazarus et al., 1987 
and Zhang et al., 2001).  
Unexpectedly, a topo I enzyme isolated from Pisum sativum (pea) showed, 
besides the typical type IB catalytic reaction, the ability to introduce positive supercoiling 
in the presence of Mg
2+
 ions, a property of reverse gyrases found only in 
hyperthermophiles (Reddy et al., 1998). This is a unique feature, not detected so far in 
any other eukaryotic topo I. 
Until recently it was thought that type IB enzymes were exclusive to eukaryotes, 
considering the complete absence of these enzymes in classic model prokaryotes (e.g. 
E.coli, Bacillus subtilis). In spite of this, the bacterium M.kandleri, a hyperthermophilic 
methanogen, contains in its complement of topoisomerases a type IB enzyme, named 
topoisomerase V (Slesarev et al., 1993). Considering that topo V is dissimilar structurally 
from all other topoisomerases there it has been proposed that it should be classified apart 
from other enzymes as type IC (Forterre, 2006). Topo V can relax both positive and 
negative supercoiling and becomes covalently attached to the 3’ end of the DNA cut, still, 
the exact role of this enzyme is not currently understood, since other hyperthermophilic 
bacteria do not seem to require one. M.kandleri is also unusual in the fact that it has a 
novel heterodimeric reverse gyrase, while all the previously discovered reverse gyrases 
are monomeric (Krah et al., 1996).  
The vaccinia virus (poxvirus) is one of the few viruses known to encode its own 
topoisomerase (Bauer et al., 1977). Coded by the E6 gene, this topoisomerase is a lot 
smaller compared to the eukaryotic type IB enzymes and was shown to be essential for 
viral proliferation in cell culture (Shchelkunov et al., 1993). 
Type II topoisomerases differ from type I enzymes in that, when bound to the 
double helix, they introduce double stranded cleavages (usually four base pair staggered). 
They can be homodimers or heterotetramers, contain two catalytic tyrosine residues (as 
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they introduce double stranded breaks) and become covalently attached to the 5’ end of 
the DNA break. They can also catenate or decatenate (knot or unknot) DNA molecules, 
by passing an intact DNA molecule through the double stranded break created, this strand 
passing activity involving ATP hydrolysis. All organisms seem to require a type II 
topoisomerase since these are the only type of enzymes capable of decatenating double 
stranded DNA molecules (i.e. newly replicated DNA) (Champoux, 2001 and Wang, 
2002). Type II enzymes are also divided into two subcategories, A and B, a distinction 
based on structural characteristics. The recent discovery of an atypical topoisomerase in 
the genome of the archebacterium Sulfolobus shibatae, named topoisomerase VI, has 
prompted the classification of this type II enzyme apart from all others, as type IIB 
(Bergerat et al., 1997).  
The type IIA enzymes are DNA gyrase and topoisomerase IV, found in eubacteria 
and topoisomerase II, found only in eukaryotes. DNA gyrase was first identified in E.coli 
as an enzyme capable of transforming a relaxed DNA molecule into a negative 
supercoiled one (Gellert et al., 1976). Indeed DNA gyrase, a heterotetramer, is the only 
enzyme known so far able to introduce negative supercoiling. This property plays an 
essential role in the initiation of DNA replication at the E.coli oriC (Fairweather et al., 
1980, Filutowicz, 1980 and Baker and Kornberg, 1988). DNA gyrase can also relax 
negatively or positively supercoiled DNA but in a much more inefficient manner, while 
its decatenation activity is almost absent in vivo (Levine et al., 1998). In the cell this 
enzyme has a role in maintaining the overall DNA superhelicity, facilitating replication 
elongation and transcription and possibly decatenation of chromosomes after DNA 
replication (Levine et al., 1998). Even though DNA gyrases are found predominantly in 
bacteria, there have been several reports of archaebacteria which also posses this type of 
enzyme (Gadelle et al., 2003). Recently, a genome analysis in the model plant A.thaliana 
revealed four putative gyrase genes and knockout studies show that all four genes are 
essential for plant development (Wall et al., 2004). Furthermore, cloning of the 
A.thaliana putative gyrase genes in E.coli gyrase temperature-sensitive strains lead to 
phenotype rescue (Wall et al., 2004). However, detailed biochemical analysis of the gene 
products is still missing for the time being. 
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Topoisomerase IV is the other main type II enzyme found in eubacteria. Topo IV 
is also a heterotetramer and a potent decatenase responsible for decatenating daughter 
chromosomes at the end of DNA replication. Like DNA gyrase, this enzyme can also 
relax negatively or positively supercoiled DNA but at a much slower rate than 
decatenation and its roles in the cell include maintaining the overall DNA superhelicity, 
facilitating replication elongation and transcription (Champoux, 2001).   
Topoisomerase II acts as a homodimer and it is the only type II topoisomerase 
found in eukaryotes (except for the newly discovered topo VI in plants). When the work 
concerning topoisomerases was just at the beginning, the identification of a type II 
enzyme in eukaryotes led to the logical assumption that its topological activity would be 
very similar to the prokaryotic type II enzymes. As it was discovered later, eukaryotic 
topoisomerase II, in spite of being homologous to both DNA gyrase and topo IV, has a 
behavior more similar to topo IV.  
Topo II can relax both negative and positive supercoiled DNA but it cannot 
perform the opposite reaction of introducing either type of supercoiling. This 
characteristic leaves the puzzling question of whether there is a yet undiscovered enzyme 
that can function as a gyrase or reverse gyrase in eukaryotes or if during evolution 
eukaryotes have lost the need for this topological reaction. In addition to the DNA 
relaxation activity, topo II is able to decatenate DNA, an enzymatic reaction essential in 
de-tangling sister chromatids at the end of DNA replication. Topo II action requires ATP 
and Mg
2+
 ions (Champoux, 2001).  The topo II decatenation reaction is illustrated in 
figure 1.3.1.2. 
In the yeasts S.cerevisiae and S.pombe topo II is absolutely required for the 
decatenation of daughter chromosomes and chromosome condensation before cell 
division (diNardo et al., 1984, Holm et al., 1985 and Uemura et al., 1987b). In 
Drosophila topo II is essential for anaphase sister chromatid separation and does have a 
partial role in chromosome condensation (Chang et al., 2003). Higher eukaryotes (with 
the exception of Drosophila) have two isoforms of this enzyme: topo II and topo II 
(Champoux, 2001). The two isozymes have a different expression pattern: topo II is 
preferentially expressed in proliferating cells while topo II apparently has the same level 
of expression in all cell types (Hsiang et al., 1988 and Turley et al., 1997). Topo II 
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seems to correspond to the yeast and Drosophila topo II, being required for chromosome 
decatenation and condensation, while topo II is not required for cell division (Nitiss, 
1998). Knockout mice for topo II die at the 4- or 8-cell stage of embryonic 
development, while knockout mice for the topo II isoform die shortly before birth and 
show abnormal neural development (Akimitsu et al., 2003a and Yang et al., 2000). So in 
spite of the fact that topo II is not essential for cell growth, it plays an important role 
during development. Furthermore, both murine embryos and HeLa cells lacking topo II, 
show an abnormal nuclear structure and go into apoptosis (Akimitsu et al., 2003b).  
 
Figure 1.3.1.2 - Topoisomerase II can pass a second DNA double helix through a induced 
DNA double strand break. The green DNA segment (T) represents the intact double 
helix, while the blue DNA segment (G) represents the cleaved double helix. The asterisks 
represent ATP binding sites (taken from Wang, 2002). 
 
Apart from these critical functions, topo II and topo II probably share with 
topo I a functional redundancy, since both type of topoisomerases seem to have a role in 
the elongation step of DNA replication, DNA transcription and genome stability (Nitiss, 
1998). 
Aside from the topoisomerases described so far, a type IIA enzyme was also 
found in the genome of three viruses: bacteriophage T4, African swine fever virus and 
paramecium Bursaria chlorella virus (Liu et al., 1979, Garcia-Beato et al., 1992 and 
Lavrukhin et al., 2000).  
As mentioned before, the discovery of a novel type II topoisomerase in Archaea 
has provoked the split of type II enzyme into two subcategories: A and B. This was due 
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to the fact that the S.shibatae topoisomerase VI, a heterotetrameric A2B2 enzyme, was not 
homologous to any other topoisomerase, but one of its subunits (subunit A) showed 
homology to Spo11p, an enzyme involved in meiotic recombination (Malone et al., 1991 
and Bergerat et al., 1997). It seems that Spo11 cleaves the DNA in order to produce the 
double stranded break required for meiotic recombination initiation. Furthermore it was 
shown that Spo11 is covalently attached to the DNA substrate much like a regular 
topoisomerase (Keeney et al., 1997). It remains to be seen if indeed Spo11 and its 
homologues in higher eukaryotes can function indeed as topoisomerases.  
Topoisomerase VI is also found in plants, as revealed from the sequencing of the 
A.thaliana genome. Since plants are normally polyploid it is thought that this enzyme 
plays a role in endoreduplication of the genome, a common event in plant development 
(Sugimoto-Shirasu et al., 2002). 
 
1.3.2 Human DNA topoisomerases and their roles in the cell. 
 
The human topoisomerase complement contains 6 enzymes: a nuclear 
topoisomerase I (topo I), a mitochondrial topoisomerase I (topo Imt), two topoisomerases 
II,  and , and two topoisomerases III,  and  (Kunze et al., 1989, Zhang et al., 2001, 
Tsai-Pflugfelder et al., 1988, Austin et al., 1993, Hanai et al., 1996 and Ng et al., 1999). 
Table 1.3.2.1 presents the human topoisomerases and their key features. 
 
















Cleaves just one DNA strand 
and becomes covalently 
crosslinked to the 3’ end of the 





 DNA transcription 
 DNA repair  
 Apoptosis 
 ? DNA replication 
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positive and negative 
supercoiling. Cannot 
catenate/decatenate, 
knot/unknot DNA molecules. 









Cleaves both DNA strands 
with a 4bp stagger and 
becomes covalently 
crosslinked to the 5’ end of the 
DNA cut. Relaxes both 
positive and negative 
supercoils. 
Catenates/decatenates, 
knots/unknots DNA molecules. 





topo II and 









 DNA replication 
termination 
(decatenation). 
 ? DNA replication 
elongation. 
Topo II  
IIA 
Cleaves both DNA strands 
with a 4bp stagger and 
becomes covalently 
crosslinked to the 5’ end of the 
DNA cut. Relaxes both 
positive and negative 
supercoils. 
Catenates/decatenates, 
knots/unknots DNA molecules. 




topo II and 
topo IIβ from 
higher 
eukaryotes. 
 Signal dependent 
transcriptional 
activation 
 ? Mitosis. 
 ? DNA replication. 
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Cleaves just one DNA strand 
and becomes covalently 
crosslinked to the 5’ end of the 
DNA cut. Relaxes only 
negative supercoiling and 
requires a region of single 
stranded DNA. The 
catenation/decatenation, 
knotting/unknotting activity 
has not been tested yet. Cannot 































The mitochondrial topoisomerase I is 601 amino acids (aa) long and highly 





 and alkaline pH for optimum activity (Zhang et al., 2001). 
Human nuclear topo I is 765aa long, has a predicted molecular weight of 91kDa 
and presents four structural domains: a N-terminal domain, non-essential for catalytical 
activity but involved in protein-protein interactions, a highly-conserved core domain 
which is in contact with DNA, a positively charged linker domain and a conserved C-
terminal domain (Stewart et al., 1996 and Champoux, 2001). It has a type IB catalysis 
with the active tyrosine (Tyr
732
) present in the C-terminal domain. As all type IB 
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enzymes it can relax both positively and negatively supercoiled DNA and shows higher 
affinity towards these two substrates than towards relaxed DNA (Zechiedrich and 
Osheroff, 1990 and Madden et al., 1995). 
In vivo topo I activity is thought to be regulated by a series of post-translational 
modifications including phosphorylation (Cardellini and Durban, 1993). p53 can 
stimulate the topo I DNA relaxing activity when bound to it (Albor et al., 1998). p53 can 
also stimulate homologous recombination (HR) in a manner strictly depending on 
topoisomerase I, while binding of poly[adenosine diphosphate (ADP)–ribose] 
polymerase–1 (PARP-1), an enzyme involved in DNA damage detection and repair, to 
topo I antagonizes this HR stimulation (Baumann et al., 2006).  
Topo I helps remove the supercoiling which accumulates during transcriptional 
elongation (Zhang et al., 1988). It also has a role in activating DNA transcription, but this 
is apparently unrelated to its catalytical activity, suggesting that topo I might be part of 
protein complexes which function as transcription activators (Kretzschmar et al., 1993).  
Topo I also has a second catalytical function as a kinase (via its C-terminal 
domain) and phosphorylates members of the SR family of RNA splicing factors (Rossi et 
al., 1996 and Rossi et al., 1998). 
In the presence of different types of DNA damage or anti-cancer drugs the 
catalytic cycle of topo I can be altered (by shifting the equilibrium towards the cleavage 
reaction or inhibiting the relegation step) and as a result topo I can remain trapped on the 
DNA as part of the cleavable complex (Lanza et al., 1996 and Pommier et al., 1998). 
However there is a mechanism for removing the topo I cleavable complex which involves 
partial enzymatic digestion of both topo I and the DNA substrate followed by cleavage of 
the tyrosyl-DNA phosphodiester linkage by the tyrosyl–DNA phosphodiesterase (Tdp1). 
For efficient hydrolysis of the cleavable complex, the Tdp1 requires that the topo I should 
be degraded to a short polypeptide and that the DNA should contain a single stranded 
region so that the 3’ end phosphotyrosyl bond is exposed (Debethune et al., 2002).  
Topo I also seems to play a role in apoptosis since high numbers of cleavage 
complexes associate with apoptotic cells (Søe et al., 2004). It has been shown that in vitro 
a topo I cleavage complex can attract a second topo I molecule that introduces another 
cut in the close proximity upstream from the original cleavage complex (Søe et al., 2001). 
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This double topo I cleavage reaction might have a role in recombination-mediated DNA 
repair (Søe et al., 2001). Furthermore in vitro p53 can stimulate the formation of these 
double topo I cleavages (Søe et al., 2002). 
Human cells contain two topoisomerase II isoforms: topo II and topo II. The  
isozyme is 1531aa long with a molecular weight of 170kDa, whereas the  isozyme is 
1625aa long and has a molecular weight of 180kDa (Tsai-Pflugfelder et al., 1988 and 
Austin et al., 1993). Even though these two isoforms are extremely similar they are 
encoded by two different genes: 17q21-22 for topo II and 3p24 for topo II. Both 
enzymes generally function as homodimers but topo II active heterodimers have been 
detected in vivo (Biersack et al., 1996). Both topo II and topo II seem to have the same 
enzymatic properties with topo II being more processive at DNA relaxation (Drake et 
al., 1989). They both also show increased affinity for supercoiled, bent and Z-form DNA 
(Austin et al., 1995, Zechiedrich and Osheroff, 1990 and Bechert et al., 1994).  
As all type II topoisomerases, they can relax positively or negatively supercoiled 
DNA but cannot introduce either type of supercoiling into DNA. They cleave double 
stranded DNA with a 4bp stagger and during this reaction they become covalently 
attached to the 5’ of the DNA molecule. They are also the only enzymes inside the cell 
able to decatenate DNA in a process where ATP binding triggers a conformational 
adjustment that facilitates the transport of a second DNA segment through the DNA 
break (Champoux, 2001). 
Topo II and topo II have different expression levels during the cell cycle: for 
topo II the mRNA abundance peaks in late S phase and during mitosis, while topo II is 
constantly expressed throughout the cell cycle (Goswami et al., 1996 and Isaacs et al., 
1998). At the same time, topo II has high levels of expression in proliferating cells 
while topo II is apparently equally expressed in all cell types (Hsiang et al., 1988 and 
Turley et al., 1997).  
Early studies on topoisomerase II (which presumably were looking at the topo II 
isoform) showed that it is part of the nuclear scaffold and is evenly distributed along the 
axial core of metaphase chromosomes (Adolphs et al., 1977 and Gasser et al., 1986). The 
main function of topo II in human cells seems to concern chromosome condensation, but 
 38 
the specific role of the two isoforms is not yet clear. It is obvious that lack of both topo 
II and topo II severely impairs chromosome condensation and proper mitotic 
segregation (Sakaguchi and Kikuchi, 2004). However, whether the two enzymes are able 
to substitute one another in this task remains an open question.  In one report topo II 
depletion alone led to failed chromosome segregation, while experiments performed in a 
different lab showed that both topo II and topo II need to be absent for failed mitosis 
(Carpenter and Porter, 2004 and Sakaguchi and Kikuchi, 2004). 
Recently it has been proposed that topo II performs its specific function during 
G2/M as part of a multisubunit complex, called the toposome (Lee et al., 2004). This 
large protein complex contains, besides the topo II enzyme, two ATPase/helicase 
proteins (RNA helicase A and RHII/Gu), one serine/threonine protein kinase (SRPK1), 
one HMG protein (SSRP1), and two pre-mRNA splicing factors (PRP8 and hnRNP C). A 
possible role for the assembly the toposome is stimulation of topo II decatenation activity 
(Lee et al., 2004).  
Topo II is also detected as part of a specific multi-protein complex involved in 
transcriptional activation of genes subjected to ligand or signal-dependent regulation (Ju 
et al., 2006). A topo II induced DNA double-stranded break leads to the activation of 
poly[adenosine diphosphate (ADP)–ribose] polymerase–1 (PARP-1), an enzyme 
involved in DNA damage detection and repair, which in turn poly(ADP-ribosyl)ates 
histone H1 and de-represses a specific chromatin locus. Therefore PARP-1 and topoII, 
along with DNA-PK/Ku86/Ku70 form a complex responsible for transcriptional 
activation in response to specific signals (Ju et al., 2006). This new topoII function 
correlates well with previous reports concerning its association with chromatin 
remodeling complexes (LeRoy et al., 2000) 
There is substantial evidence that both topo II  and  are in vitro substrates for 
casein kinase II and protein kinase C, while topo II can also be phosphorylated by 
protein kinase A (Wells et al., 1994, Watt and Hickson, 1994 and Isaacs et al., 1998). In 
mitosis both isozymes seem to be hyperphosphorylated but the exact role of this 
modification is not well understood (Kimura et al., 1994 and Kimura et al., 1996). Also, 
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both human topo II  and  can substitute the S.cerevisiae topo II enzyme in 
chromosome condensation and recombination (Jensen et al., 1996). 
Human cells contain two topoisomerase III isoforms: topo III and topo III. The 
topo III gene, found on chromosome 17p11.2-12, codes for two variants of 1001aa and 
976aa respectively of this enzyme, due to the presence of two alternative start codons 
(Hanai et al., 1996). The topo III gene on chromosome 22q11-12 encodes three 
alternatively spliced transcripts to give rise to three protein variants, 862aa 730aa and 
707aa long (Kawasaki et al., 1997 and Ng et al., 1999). 
Characterization of the topo III enzyme shows that it is a classical type IA 
topoisomerase which is able to cleave negatively supercoiled DNA in the presence of a 
single-stranded region and requires Mg
2+
 ions for catalytical activity (Goulaouic et al., 
1999). Even though the same type of characterization is not yet available for topo III, 
the high-homology between the two enzymes and the fact that topo III expression in 
yeast cells was shown to rescue at least in part the S.cerevisiae top3 phenotype strongly 
indicate that also topo III is a classical IA topoisomerase (Ng et al., 1999). 
Topo III interacts with BLM and its supercoiling relaxation activity is stimulated 
by it, while both topo III and III interact with the RecQ5 helicase (Wu and Hickson, 
2002 and Shimamoto et al., 2000). Ataxia telangiectasia (AT) is a recessive disorder 
which shares some of the features of Bloom’s syndrome and knock down of topo III 
protein levels or overexpression of a truncated form of the enzyme has been shown to 
partially rescue the AT phenotype in cell culture (Fritz et al., 1997). The topo III 
interaction with the Bloom’s syndrome helicase in vivo might be required in solving a 
recombination intermediate containing a double Holliday junction (HJ) (Wu and 
Hickson, 2003). 
Topo III is present both in the nucleus and mitochondria, while topo III is 
exclusively nuclear, moreover topo III seems to be concentrated in the nucleoli, 
possibly required for rDNA metabolism (Lin et al., 2000 and Wang et al., 2002). There 
seems to be a difference in the levels of topo III enzyme in cycling versus non-cycling 
cells, with apparent high-levels of proteolytic cleavage of the isoform in resting cells (Lin 
et al., 2000). Topo III was also reported to associate with telomeres, while topo III 
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associates with metaphase chromosomes (Kobayashi and Hanai, 2001 and Tsai et al., 
2006).  
 
1.3.3 Topoisomerase inhibitors. 
 
DNA topoisomerase inhibitors are drugs which either poison the enzyme, by 
inhibiting the religation step and transforming the enzyme in a DNA damaging agent, or 
they inhibit the DNA relaxation or decatenation activity and therefore mimic a null 
mutation. These agents are currently used in the treatment of bacterial infections and also 
represent one of the major classes of anti-cancer drugs used in the clinic. Topoisomerase 
inhibitors have been discovered only for type IB and type II enzyme, no report of type IA 
inhibitors has been published so far.  
The first eukaryotic topo I inhibitor identified was camptothecin (CPT) an 
alkaloid with potent anti-tumor activity from the tree Camptotheca acuminate (Wall et 
al., 1966 and Hsiang et al., 1985). Camptothecins (CPT and its derivatives) are five-
member ring alkaloids which inhibit specifically the religation step in the catalytic cycle 
of topo I (Hsiang et al., 1985). They do not interact with either the DNA or the enzyme 
alone but form a ternary complex by binding at the topo I - DNA interface and blocking a 
specific conformational state of the enzyme – DNA complex (namely the cleavage 
complex) resulting in a special case of noncompetitive inhibition called interfacial 
inhibition (Pommier and Cherfils, 2005). As a result of this inhibition the enzyme is left 
covalently attached to the 3’ end of the DNA substrate and in addition its DNA relaxation 
activity is inhibited. Figure 1.3.3.1 illustrates CPT and a few derivatives.  
Currently two CPT derivatives are used in cancer therapy: hycamtin 
(Topotecan®) and CPT-11 (Camptosar®). Topotecan is effective in the treatment of 
advanced colorectal carcinomas while Camptosar is prescribed to patients with ovarian 
and small-cell lung cancers (Pommier and Cherfils, 2005). In spite of their excellent anti-
cancer activity CPT and its derivatives have tree main disadvantages in vivo: they are 
toxic, the topo I inhibition is reversible within minutes upon drug removal and at 
physiological pH they reach quickly equilibrium with their carboxylate derivate which is 
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inactive (Pommier et al., 1998). Currently the family of CPT derivatives is ever 
expanding in the search for more potent drugs with less side effects.  
 
Figure 1.3.3.1 - CPT and its derivatives (Taken from Takimoto et 
al., 1998).
 
Other topo I inhibitors of the religation reaction include a series of DNA intercalating agents 
like benzoanthracenes (e.g. saintopin and derivatives), benzophenanthridines and protoberberines, 
indolocarbazoles (e.g. NB-506 and KT6006), intoplicine and anthracyclines 
(e.g.morpholinodoxorubicin and aclacinomycin). Some of these compounds are not specific for topo I 
and have been shown to inhibit topo II also (e.g. intoplicine) (Pommier et al., 1998). 
It is worth mentioning that a series of endogenous and exogenous DNA damaging agents also 
lead to the freezing of the topo I – DNA cleavage complex. Amongst these the most common are 
ultraviolet (UV) irradiation, alkylating and intercalating agents (Lanza et al., 1996). 
A range of drugs capable of binding or intercalating DNA such as doxorubicin, aclacinomycin 
A and naphthacenecarboxamide antibiotics have been reported to inhibit the topo I forward cleavage 
reaction, but their specificity towards topo I is questionable (Pommier et al., 1998). 
Epipodophyllotoxins are synthetic derivatives of podophyllotoxins, naturally occurring lignants 
found in plants, particularly in the genus Podophyllum but found also in other genera. They inhibit 
specifically the religation step in the catalytic cycle of eukaryotic topoisomerase II (Minocha and Long, 
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1984). They are also thought to be interfacial inhibitors and form ternary complexes at the topo II - 
DNA interface (Pommier and Cherfils, 2005).  
In contrast to topo I, the stabilized topo II – DNA covalent complex consists of the enzyme 
being covalently bound to the 5’ end of the break. 4’-demethylepipodophyllotoxin-4-(4,6-O-ethylidene-
beta-D-glucopyranoside) (also known as etoposide or VP16) and 4’-demethylepipodophyllotoxin-4-
(4,6-O-thenylidene-beta-D-glucopyranoside (also known as teniposide or VM26) are two of the most 
used epipodophyllotoxin inhibitors. Figure 1.3.3.2 illustrates the structure of etoposide and teniposide.
  
Etoposide is a widely used anticancer drug in the therapy of testicular cancer, small cell lung 
cancer, lymphomas, Ewing's sarcoma, Kaposi's sarcoma, ovarian cancer (Damayanthi and Lown, 
1998).  Teniposide is used in poor prognosis acute lymphoblastic leukemia (Damayanthi and Lown, 
1998).   
 
Figure 1.3.3.2 - The epipodophyllotoxins (Taken from Hande, 1998). 
 
Anthracycline antibiotics are another group of topoisomerase II inhibitors used in 
cancer therapy, originally isolated from fermentation products of Streptomyces peucetus. 
They have a range of effects in vivo apart from topo II inhibition, which include a DNA 
intercalating effect, inhibition of helicase activity and induce free-radical formation. 
Nevertheless the main tumor-cell killing effect is thought to be due to topo II poisoning. 
There are four anthracyclines currently in clinical use: doxorubicin (lymphomas, breast 
cancer, sarcomas, Kaposi's sarcoma and leukemias), daunorubicin (acute lymphocytic 
leukemia), idarubicin (acute myelogenous leukemia) and epirubicin (lymphomas, breast 
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cancer, sarcomas, Kaposi's sarcoma and leukemias) (Hortobagyi, 1997). Figure 1.3.3.3 
illustrates the anthracycline antibiotics in clinical use. 
 
 
Figure 1.3.3.3 - The anthracycline antibiotics in clinical use (Taken from Hande, 1998). 
 
 Mitoxantrone is the only anthracenedione topo II inhibitor currently in clinical 
use. It is a compound similar to the anthracycline antibiotics, but it has a reduced ability 
to form free-radicals, and therefore reduced toxicity. It is used in the treatment of breast 
cancer, prostate cancer, leukemia (myelocytic) and lymphoma (Hande, 1998). Figure 
1.3.3.4 illustrates the structure of mitoxantrone.  
 
 
Figure 1.3.3.4 - The structure of mitoxantrone (Taken from Hande, 1998). 
 
Similar to topo I, topo II cleavage is also induced by certain types of DNA damage but, in 
contrast to topo I, UV irradiation does not trap the enzyme cleavable complex on the DNA (Kingma et 
al., 1997 and Rosenstein et al., 1997). 
The quinolones nalidixic acid and its derivatives, norfloxacin, enoxacin, lomefloxacin, 
ciprofloxacin, ofloxacin, levofloxacin, and sparfloxacin are very potent antibiotics used against Gram-
positive and Gram-negative bacteria (Hooper, 1998).  Their primary mode of action is inhibition of 
bacterial DNA gyrase and topoisomerase IV, much like epipodophyllotoxins inhibit eukaryotic 
topoisomerase II (Kreuzer and Cozzarelli, 1979). 
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Coumarins are a different class of antibiotics which inhibit DNA gyrase by competitive 
inhibition of ATP binding, and include novobiocin, coumermycin A1, and chlorobiocin (Lewis et al., 
1996).  
 
1.3.4 Topoisomerases in DNA replication. 
 
As a process DNA replication can be divided into three steps: initiation, elongation and 
termination. During initiation the pre-replicative complex assembled at the origin of DNA replication 
gets converted into two replication forks which will start to replicate the two parental DNA strands in 
opposite directions. This initiation step of DNA synthesis requires the origin DNA be melted. 
In elongation the two fork complexes continue to unwind and replicate simultaneously both 
parental DNA strands. The DNA unwinding performed by the fork leads to the accumulation of 
positive supercoiling (see figure 1.2.3.1). When two replication forks, from adjacent replicons, 
converge and finish replicating a DNA segment, termination occurs. At this stage the two daughter 
double helices will be intertwined in a structure called a catenate (see figure 1.2.3.2). 
As mentioned previously topoisomerases are enzymes essential for dealing with the topological 
constraints of DNA during replication. In an overly simplified view they are needed to solve three 
topological problems in replication: the unwinding of the origin, removal of supercoiling during 
elongation and decatenation of sister chromatids at termination. 
Table 1.3.4.1 illustrates the current knowledge about the topoisomerases involved in DNA 
replication. 
 








In vivo - DNA gyrase. 
In vitro - DNA gyrase 
or topo IV. 
In vivo - DNA gyrase. 
In vitro - DNA gyrase, 
topo III or topo IV. 
In vivo - topo IV. 




In vivo - none. 
In vitro - none. 
In vivo - topo I, topo II 
and/or topo III. 
In vitro - topo I. 
In vivo - topo II. 
In vitro - ?. 
Viruses - 
SV40 
In vitro - topo I. 
In vitro - topo I ot topo 
II. 
In vitro - topo II. 
Human ? ? topo I or topo II. In vivo - topo II. 
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DNA replication has been characterized in detail in bacteria. In E.coli the initiation of DNA 
replication at oriC requires origin binding by the dnaA protein which induces a local melting of the 
duplex. Further binding of the dnaB (helicase) and dnaC leads to the formation of the pre-priming 
complex. In turn DNA gyrase, the only known topoisomerase able to introduce negative supercoiling, 
enlarges the melted region to allow RNA priming and subsequent fork movement (Gellert et al., 1976 
and Sekimizu et al., 1988). Both in vivo and in vitro initiation of DNA synthesis seems to require the 
activity of DNA gyrase (Fairweather et al., 1980, Filutowicz, 1980 and Baker and Kornberg, 1988). 
Nevertheless, is seems that, in vitro, topoisomerase IV can substitute to some extent DNA gyrase in the 
initiation event (Smelkova and Marians, 2001). This is unusual considering that topo IV cannot 
introduce negative supercoiling and its DNA relaxation activity is quite poor (topo IV is a potent 
decatenase).  
Gyrase has a particular mode of action: approximately 140bp of DNA is wrapped around the 
enzyme in a right-handed manner and the negative supercoiling is introduced by an intramolecular 
strand passage mechanism, in which the DNA wrapped around the enzyme is cleaved and another 
region of the same molecule is passed through the double-stranded break (Liu and Wang, 1978a, Liu 
and Wang, 1978b and Ullsperger and Cozzarelli, 1996). DNA gyrase prefers relaxed and positively 
supercoiled DNA as a substrate but the exact mechanism by which it is recruited at the origin in a 
timely fashion is unknown (Higgins and Cozzarelli, 1982).  
In vitro DNA elongation in E.coli can be supported by either gyrase, topo III or topo IV and 
presumably in vivo all these enzymes contribute to DNA relaxation to different extents (Hiasa and 
Marians, 1994a and Hiasa and Marians, 1994b).  
The enzyme responsible for in vivo decatenation of replicating daughter DNA molecules at the 
termination step of DNA replication is topoisomerase IV (Adams et al., 1992 and Zechiedrich and 
Cozzarelli, 1995). Nonetheless in vitro both topo IV and topoisomerase III can perform this action 
(Hiasa et al., 1994). This finding is interesting since topo III does not introduce double stranded breaks 
in the DNA, therefore it acts before the replication is complete or can take advantage of an already 
present single-stranded nick.  
In eukaryotes DNA replication is a much more complex process, which involves many levels of 
regulation including origin decision, timing of origin firing and inhibition of origin re-firing. All these 
features relate to the high complexity genomes which characterize eukaryotes. Even though many basic 
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features of eukaryotic DNA replication are currently known a thorough understanding of the process is 
still lacking. 
The most detailed understanding of the role of DNA topoisomerases in DNA replication has 
come from yeast experiments. Initiation of DNA replication does not seem to require any 
topoisomerase. Double mutants of topo I and topo II can still synthesize short DNA molecules, even 
though their DNA replication is severely impaired (Kim and Wang, 1989 and Brill et al., 1987). 
Topoisomerase III might act at the initiation step to facilitate the residual DNA replication observed but 
this is highly unlikely.  
Cells containing mutated topo I or topo II can essentially complete one round of DNA 
replication. Nevertheless topo I inactivation leads to delays in chain elongation in early S-phase, while 
cells lacking topo II cannot decatenate the sister chromatids at the end of DNA replication and have 
broken chromosomes in mitosis (Brill et al., 1987 and Kim and Wang, 1989). This indicates that both 
topo I and topo II can relieve supercoiling during elongation but topo II is the enzyme responsible for 
DNA decatenation. 
Interestingly, in a yeast in vitro system, efficient plasmid replication was dependent on topo I 
activity and not topo II suggesting that at least in this case topo II is unable to support replication 
elongation (Mitkova et al., 2005).  
Topoisomerase III mutants in S.cerevisiae exhibit a slow growth phenotype suggesting that this 
enzyme might also be involved in replication elongation (Gangloff et al., 1999). This potential role 
might be connected with the reported interaction of topo III with helicases, a known component of 
replication forks (Bennett et al., 2000). Instead, the topo III enzyme is essential in the yeast S.pombe 
and its presence is required for accurate DNA replication and chromosome segregation (Maftahi et al., 
1999 and Oh et al., 2002). 
In human cells there is some evidence that topo II interacts preferentially with nascent DNA 
(Qiu et al., 1996). Topoisomerase I and II could be isolated as part of a large protein complex called the 
synthesome which includes DNA polymerases alpha, delta and epsilon, proliferating cell nuclear 
antigen, replication factor A, replication factor C, flap endonuclease 1 and DNA ligase I, all members 
of replication forks (Jiang et al., 2002 and Sandoval et al., 2005). 
Another way to investigate the requirement of DNA replication for topoisomerases in human 
cells has been by the study of viruses since they normally use the host cell proteins for replication. 
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Replication of simian virus 40 (SV40) DNA relies on the sequential binding of two hexamers of 
T antigen (a helicase) to the SV40 origin followed by the recruitment of DNA polymerase/primase, 
replication protein A (RPA) and topoisomerase I (Simmonds et al., 2004). Nucleolin seems to associate 
with T antigen hexamers and topo I at the replication fork to form a DNA unwinding and relaxation 
complex, which is essential for initiation of viral replication (Seinsoth et al., 2003). Instead, topo II can 
replace topo I during elongation but is absolutely required for decatenation of daughter chromatids at 
the end of SV40 replication (Yang et al., 1987 and Ishimi et al., 1995). 
Herpes simplex virus 1 (HSV-1) replication-dependent recombination requires the assembly of 
a replication fork that involves the viral replication proteins, including the polymerase catalytic subunit 
(UL30), processivity factor (UL42), helicase-primase core enzyme (UL5/UL52), loading factor (UL8), 
SSB (ICP8), and a relaxing enzyme e.g. eukaryotic topoisomerase I. (Nimonkar and Boehmer, 2003). 
In addition inhibition of topo II activity prevents efficient replication of both HSV-1 and HSV-2 
(Nishiyama et al., 1987 and Hammarsten et al., 1996).  
Both topoisomerases I and II are also involved in the replication of Epstein-Barr virus and 
adenovirus, while topo I might have a role in parvovirus replication (Schaak et al., 1990, Gu and 
Rhode, 1991 and Kawanishi, 1993).  
To conclude there is a lot of indirect evidence that both topo I and topo II are involved in 
human DNA replication, but their exact role is far from characterised. 
 
1.4 The human lamin B2 origin - a tool for studying the role of DNA topology in DNA replication. 
 
The human origin of DNA replication located close to the lamin B2 gene on chromosome 
19p13.3 is currently the best characterized human origin. This origin is positioned at the 3’ end of the 
lamin B2 gene and close to the promoter of the housekeeping gene TIMM13 (Giacca et al., 1994).   
It is an early firing origin which has been shown to be active in a variety of normal and cancer 
cell-lines and to be covered by a proliferation-dependent footprint which varies dynamically with the 
cell-cycle (Dimitrova et al., 1996 and Abdurashidova et al., 1998). This footprint covers the very end of 
the lamin B2 transcribed region along with a part of the downstream intergenic spacer. The structure of 
the footprint is asymmetric on the two complementary strands with a larger area protected on the lower 
strand and this region is protected in both G1 and S phases of the cell cycle but not in M 
(Abdurashidova et al., 1998). 
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The start-site of bi-directional DNA replication has been mapped with nucleotide resolution and 
it shows that the DNA synthesis begins with a 4 nucleotide overlap in the footprinted region 
(Abdurashidova et al., 1999). 
Furthermore, in-vivo studies have shown that the hOrc1, hOrc2, hCdc6 and hMcm3 proteins, 
known members of eukaryotic pre-replicative complexes (pre-RC), are in direct contact with the origin 
sequence at different moments of the cell cycle (Abdurashidova et al., 2003).  
The origin recognition complex (ORC) is a six subunit protein complex (Orc1-6) which marks 
in G1 genomic loci which will be used as replication origins in S phase (Mendez and Stillman, 2003). 
Cell division cycle 6 (CDC6) is a member of the AAA+ ATPases protein family which is essential in 
the formation of pre-RC as it helps with the binding of the mini-chromosome maintenance (MCM) 
proteins (Mendez and Stillman, 2000). MCM 2-7 proteins form a hexameric molecule which is thought 
to act as a DNA helicase at the replication fork (Labib and Diffley, 2001). 
Nucleotide-level investigation, of the lower strand only, shows the position bound by the hOrc1, 
hOrc2 and hCdc6 proteins at the origin, throughout the cell cycle (Abdurashidova et al., 2003). In M 
phase, in good agreement with the lack of a protein footprint at the origin, none of these proteins were 
found on the DNA (Abdurashidova et al., 1998). In the middle of G1 Orc1, Orc2 and Cdc6 are located 
at the lamin B2 origin as part of the pre-replicative complex. In the middle of S, after the origin has 
fired, only the Orc2 protein is still bound on the DNA, moreover its position has been shifted closer to 
the start-site (Abdurashidova et al., 2003). Figure 1.4.1 illustrates the current known facts about the 
lamin B2 origin. 
Considering the lack of knowledge about the involvement of human DNA topoisomerases in 
the initiation step of DNA synthesis, the lamin B2 origin represents the perfect tool for investigating 
the importance of topology and topology modifying enzymes at the origin.  
Both human topo I and topo II are targets of anti-cancer drugs which offer a specific method for 
topo - DNA crosslinking in the cell. If indeed these enzymes interact with the lamin B2 origin, their 
position on the DNA would be easily identifiable. Data on the SV40 replication origin hints at a 
possible interaction between a topoisomerase (topo I), a helicase (T-antigen) and DNA polymerase 
alpha/primase at the origin (Simmons et al., 2004). Furthermore, the stabilizing effect of nucleolin on 
the topo I - T-antigen complex suggests a helicase-topoisomerase association at the SV40 replication 
fork (Seinsoth et al., 2003). Such interactions would also be beneficial for human origins of DNA 
replication and their replication forks. 
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Topo II, on the other hand, is considered a ‘bona fide’ member of the nuclear scaffold and it has 
















anchored to the nuclear matrix or not and a detailed analysis of the topo II interaction with the origin 








Figure 1.4.1 The lamin B2 origin of DNA replication. The genomic region 
containing the origin is shown in the upper part, lamin B2 and ppv1 (now called 
TIMM13) are the two genes found close by. B48 and B13 correspond respectively to the 
origin and non-origin region used for competitive PCR analysis. The highlighted 
sequences correspond to the protein footprint at the origin (shown for the lower strand 
only). The arrows indicate the position of the origin bound proteins with respect to the 
start-sites, footprint and phase of the cell cycle (taken from Abdurashidova et al., 2003). 
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2. MATERIALS AND METHODS 
 
2.1 Cell culture and synchronization. 
  
Adherent HeLa cells (ATCC Number: CCL-2) were cultured in D-MEM/F-12 (1:1) with 
GlutaMAX™ I (Invitrogen) supplemented with 10% fetal calf serum (Invitrogen) and 50g/ml 
gentamicin kept in a 5% CO2 atmosphere at 37°C. Exponentially growing cells were arrested in M 
phase by incubation with nocodazole (Sigma) 50 ng/ml final concentration. Mitotic cells were 
recovered by mechanical shake-off 16 hours later, washed from nocodazole and replated in 
nocodazole-free medium. The start of G1 phase was considered when the cells were plated in complete 
medium. At different points of the G1 phase unattached cells were washed away and only those cells 
still firmly attached were used. To arrest cells in late G1 - G1/S border M cells were released in 
complete medium for 5 hours and then were incubated with either mimosine (Sigma), 5mM final 
concentration, for 24 hours or aphidicolin (Sigma), 5g/ml, for 16 hours. The mimosine synchronized 
cells will be referred to as late G1 - G1/S border, while aphidicolin synchronized cells will be 
considered G1/S border-early S. Cells synchronized with aphidicolin were then washed three times 
with complete medium and released for different lengths of time to give different S phase populations. 
The start of S phase was considered after the third wash in complete medium. Cell cycle progression 
was followed by flow-cytometric analysis shown in figure 2.1.1. 
 
2.2 Mapping of topoisomerase I in vivo. 
 
For each experiment ~ 10
7
 HeLa cells were incubated with 1M CPT (Sigma) or 10M 
gimatecan in complete medium for 1 minute, washed twice with warm PBS containing the same 
amount of drug to avoid reversal of cleavable complexes and lysed in 1.5ml buffer A (250mM Tris 
pH8, 25mM EDTA, 5mM NaCl, 0.5% SDS, 800g/ml Proteinase K) supplemented with 1M CPT. 
Gimatecan was synthesized according to published protocols by Sotir Zahariev (Dallavalle et al., 2001 
and Wadkins et al., 2004). 
 




Figure 2.1.1 - FACS analysis of HeLa cells synchronized throughout the cell cycle. Starting from top 
left asynchronous, M, G1 30 minutes, G1 1 hour, G1 5 hours, G1 7 hours, late G1 – G1/S border 








cleavage, CPT treated cells were 
washed from the drug and left in 
complete medium for 5 minutes, 
washed twice with PBS and lysed in 
buffer A. For the checkpoint inhibition 
experiments, HeLa cells were 
with 1M CPT and 5mM caffeine incubated simultaneously 
(Sigma) for 5 minutes, the cells were then washed with PBS supplemented with 1M CPT and 
immediately lysed in lysis buffer A containing 1M CPT. Cell lysates were incubated overnight at 
37°C, total genomic DNA was isolated by phenol/chloroform/isoamyl alcohol extraction followed by 
ethanol precipitation and resuspended in 20l TE buffer pH7.5 (1mM EDTA, 10mM Tris-HCl pH7.5). 
The free 5’ ends of the DNA were phosphorylated by incubation with 2μl T4 polynucleotide kinase 
(10U/μl) (New England Biolabs) in 10X T4 polynucleotide kinase buffer, containing 1mM ATP, for 1 
hour at 37°C. The DNA was re-purified by proteinase K treatment, phenol/chloroform/isoamyl alcohol 
extraction and ethanol precipitation. The topo I cleavage sites were then detected by LMPCR analysis. 
The primer sets used for both LM and TDPCR are shown in table 2.2.1 and the procedure for LMPCR 
has been described in detail elsewhere (Dimitrova et al., 1996 Abdurashidova et al., 2000 and Mueller 
et al., 2001).  
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Table 2.2.1 – Position of the sequence specific primers used for LM and TDPCR 
analysis at and around the lamin B2 origin. The numbering corresponds to the 
GeneBank accession number M94363. 
Name Sequence Genomic 
position 
A A1 5’ TTACCTACACGAGCTACCCGTGGTT 3’ 
A2 5’ TGGTGCGACTCCGCGGGAAGA 3’ 




B B1 5’ GGCTAGTGTAGCTAGTGTAAACAGGACC 3’ 
B2 5’ GTAAACAGGACCCAGGCGATGCATG 3’ 




C C1 5’ TCGCATCACGTGACGAAGAGTCAGC 3’ 
C2 5’ GAGTCAGCTTGTGCAACAGCGTCGG 3’ 




D D1 5’ GTCACAGCACAACCTGCAAAAACGG 3’ 
D2 5’ CAAAAACGGAGCTGGGCTGCAGCTG 3’ 




E E1 5’ GGGGTGGAGGGATCTTTCTTAGACA 3’ 
E2 5’ GACATCCGCTTCATTAGGGCAGAGGCC 3’ 




F F1 5’ GAGTCCCTCAGATCTTTAACAAAGAACTGC 3’ 
F2 5’ AACTGCCGCGTGCAGGCTTCAGACC 3’ 




G G1 5’ TGCACAGCGCCAGGTTAACGC 3’ 
G2 5’ CAGGTTAACGCTGAAGCCTGCCCCG 3’ 






In brief, 4µl total genomic DNA was heat denatured and annealed to 0.1pmol of primer 1 for 30 
minutes, at 60°C, in 10µl final volume of 1x Vent polymerase buffer. Primer extension was performed 
in 20µl final volume in the presence of 0.5mM dNTPs and 1U of Vent polymerase exo(-) (New 
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England Biolabs), for 5 minutes at 60°C, 10 seconds at 65°C, 10 seconds at 70°C and elongated 10 
minutes at 76°C. The ligation reaction contained the 20l of the primer extension reaction to which 
23l PEG-40, 5l 10x T4 DNA ligase buffer and 2l T4 DNA ligase (400U/l) (New England 
Biolabs) were added. The ligation was performed overnight at 4°C. After the ligation step, samples 
were purified by phenol extraction and ethanol precipitation and PCR amplification was performed in 
1x Vent buffer, in the presence of 10pmol of primer 2, 10pmol of a primer complimentary to the 
asymmetric linker, 0.2mM dNTPs and 4mM MgSO4, with 1U of Vent polymerase in a final volume of 
50µl. The amplification conditions were: 3 minutes denaturation at 95°C, 18 cycles of 1 minute 
denaturation, 2 minutes annealing and 3 minutes extension at 76°C, with 5 seconds further extension 
added at each cycle, and a final extension step of 7 minutes at 76°C. 20µl of amplified product was 
used for a final hot extension reaction with 3μl 10X Vent buffer, 0.6μl MgSO4 (100mM), 1μl dNTPs 
(10mM each), 4μl of primer 3 labeled with
 33
P-γATP (2 pmols), 1.15μl H2O and 0.25μl Vent Exo- 
(2U/μl) (New England Biolabs). The hot extension program included a first denaturation step of 5 
minutes, then 5 cycles of 1 minute denaturation, 2 minutes annealing and 5 minutes of polymerase 
extension at 76°C followed by a final elongation step at 76°C for 5 minutes. The hot extension product 
was then phenol/chloroform/isoamyl alcohol treated, precipitated with ethanol and resuspended in a 
sample buffer containing formamide. Before loading on a 7% acrylamide 6M urea sequencing gel the 
sample was denatured for 3 minutes at 95°C and then cooled in ice. The gel was run at 70W for 1h, 
dried and autoradiographed using a Kodak Biomax MR film. 
 
2.3 Mapping of topoisomerase II in vivo. 
 
For each experiment ~ 10
7
 HeLa cells were incubated with 10nM VP16 (Sigma) in complete 
medium for 1 minute, washed twice with PBS containing the same amount of drug to avoid reversal of 
cleavable complexes and lysed in 1.5ml buffer A supplemented with 10nM VP16. To check reversal of 
drug induced cleavage, treated cells were washed from the drug and left in complete medium for 5 
minutes, washed twice with PBS and lysed in buffer A. Cell lysates were incubated overnight at 37°C, 
total genomic DNA was isolated by phenol/chloroform/isoamyl alcohol extraction followed by ethanol 
precipitation and resuspended in 20l TE buffer pH7.5. The topo II cleavage sites were detected by 
TDPCR analysis and the position of the primers used is shown in table 2.2.1. The TDPCR procedure 
has been described in detail elsewhere (Komura and Riggs, 1998). 
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Typically 4µl total genomic DNA was mixed with 3μl 10X Vent buffer, 1μl MgSO4 (100mM), 
1μl dNTPs (10mM each), 0.6µl primer 1 (10pmol/µl), 1μl Vent Exo- (2U/μl) and H2O up to 30µl total 
volume. The extension mix was incubated at 95°C for 5 minutes then at 95°C for 1 minute, 60°C for 2 
minutes, 76°C for 7 minutes, cycled 10 times, with a final incubation at 76°C for 3 minutes. The 
extension products were then ethanol precipitated and resuspended in 10μl 0.1x TE pH 7.4 to which 
4μl 5x TdT buffer, 4μl rGTP (10mM) (Promega), 1.33μl H2O and 0.67μl TdT (15U/μl) (Invitrogen) 
was added. The ribotailing reaction was incubated at 37°C for 15 minutes after which the DNA was 
ethanol precipitated again and resuspended in 20μl H2O. For the ligation reaction 23l PEG-40, 5l 
10x T4 DNA ligase buffer and 2l T4 DNA ligase (400U/l) (New England Biolabs) were added to the 
DNA and the sample was incubated overnight at 4°C. After the ligation product was purified by phenol 
extraction and ethanol precipitation the PCR amplification and the hot extension were performed as for 
the LMPCR (see above). 
For immunoprecipitation of topo II-DNA covalent complexes, HeLa cells incubated with 10nM 
VP16 were washed twice with PBS containing 10nM VP16 and lysed with a solution of 1% sarkosyl in 
TE pH 8 (10mM Tris-HCl pH8, 1mM EDTA). The lysates were layered on top of a CsCl solution, 1.5 
g/ml density and the samples were centrifuged at 70000rpm for 5 hours at 20ºC in a Beckman L8-70M 
Ultracentrifuge in order to separate the bulk DNA and protein-DNA complexes (bottom fraction) from 
free proteins (top fraction). The cellular DNA was collected, washed twice in TE buffer pH8 and twice 
in restriction enzyme buffer. The DNA was incubated with 100U of BstNI restriction enzyme for one 
hour at 37°C, washed three times in TE buffer pH8 and dissolved in ChIP lysis buffer (1% SDS, 10mM 
EDTA, 50mM Tris HCl pH8.1). Chromatin immunoprecipitation using a goat polyclonal anti-
topoisomerase II antibody (Santa Cruz) was performed using the Chromatin immunoprecipitation assay 
kit (Upstate Biotechnology) as described by the manufacturer. The immunopurified DNA was isolated 
by proteinase K treatment, phenol extraction and ethanol precipitation and subjected to TDPCR 
analysis as described above. 
 
2.4 UV laser photo-footprinting. 
 
Asynchronous HeLa cells growing in 5cm diameter Petri dishes were treated for 1 minute with 
either 1M CPT or 10nM VP16, washed with PBS containing the same drug concentration and UV 
laser irradiated at two wavelengths, obtained by frequency conversion of infrared femtosecond pulses 
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produced by a Ti:sapphire system (Russman et al., 1998). Second and third harmonic light pulses at 
400 and 266nm, of duration 120fs and 200fs, pulse energy of 25 and 40J, respectively, were produced 
in two consecutive BBO crystals and expanded to a diameter of about 60mm to allow simultaneous 
irradiation of the surface of the dish. For comparison, HeLa cells not treated with the drugs were 
irradiated in the same conditions. The cells were immediately lysed in lysis buffer A after irradiation, 
the DNA isolation and TDPCR were performed as described above.  
 
2.5 BrdU labeling. 
 
HeLa cells synchronized with mimosine were treated with 1M CPT in complete medium 
containing mimosine for 30 minutes, washed from mimosine in complete medium containing 1M 
CPT and pulsed with 50M BrdU (Sigma) in the presence of CPT for 30 minutes. The cells were 
washed first from BrdU with complete medium supplemented with 1M CPT, after were washed from 
the drug and left in complete medium for 10 minutes. As a control, late G1 - G1/S synchronized cells 
were incubated with BrdU for 30 minutes in the presence or absence of mimosine, washed and released 
in complete medium for 10 minutes. Nascent DNA was isolated as described below (section 2.6). 
 
2.6 Nascent DNA isolation and competitive PCR. 
 
HeLa cells were collected by scraping, resuspended in PBS containing 10% glycerol and lysed 
for 10 minutes in the wells of a 1.2% alkaline agarose gel immersed in alkaline running buffer: 50mM 
NaOH, 1mM EDTA. The gel was run for 16 hours at 2V/cm and the nascent DNA of size 0.6-1 kb was 
isolated from the gel using a Qiagen Gel Extraction kit. BrdU-enriched sequences were 
immunoprecipitated using anti-BrdU antibody (Abcam) as described by the manufacturer. The isolated 
nascent DNA was analyzed by competitive PCR. The quantification of the abundance of the origin 
(B48) and non-origin (B13) DNA fragments was performed as described previously (Diviacco et al., 
1992). The primers used for the B48 amplification are: B48 Dx 5’GACTGGAAACTTTTTTGTAC3’, 
B48 Sx 5’ TAGCTACACTAGCCAGTGACCTTTTTCC 3’. The B48 amplification reaction contained 
5l 10x Taq polymerase buffer with 15mM MgCl2, 2.7l 25mM MgCl2, 1l (10pmol) of each primer, 
1l dNTPs (10mM each), 0.25l Taq polymerase (2U/l) (Promega), 5l nascent DNA, 5l competitor 
DNA and H2O up to 50l. The primers used for the B13 amplification are: B13 Dx 5’ 
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GCCAGCTGGGTGGTGATAGA 3’, B13 Sx 5’ CCTCAGAACCCAGCTGTGGA 3’. The B13 
amplification reaction contained 5l 10x Taq polymerase buffer, 3l 25mM MgCl2, 1l (10pmol) of 
each primer, 1l dNTPs (10mM each), 0.25l Taq polymerase (2U/l) (Promega), 5l nascent DNA, 
5l competitor DNA and H2O up to 50l. The amplification conditions for both B48 and B13 were: 
95°C 5 minutes, (95°C 30 seconds, 56°C 30 seconds, 72°C 30 seconds) cycled 35 times, 72°C 5 
minutes. 
 
2.7 Trichostatin A (TSA) treatment. 
 
Asynchronous growing HeLa cells were incubated for 1 or 4 hours with 100ng/ml TSA (Sigma) 
in complete medium, then incubated with 1M CPT or 10nM VP16 in complete medium for 1 minute, 
washed twice with PBS supplemented with the same drug concentration and lysed in buffer A 
containing the same amount of drug. The topo I and topo II covalent complexes were detected by 
LMPCR or TDPCR analysis, respectively, as described above (sections 2.2 and 2.3).  
 
2.8 In vivo crosslinking  
 
2.8.1 Topoisomerase I. 
 
HeLa cells synchronized at the late G1 - G1/S border were crosslinked with 1% formaldehyde 
(Merck) in PBS for 5 minutes. The reaction was stopped by adding a cold solution of 125mM glycine 
in PBS, cells were washed twice in cold PBS and incubated, for 10 minutes on ice, with RSB buffer 
(10mM Tris-HCl pH 8.0, 10mM NaCl, 3mM MgCl2) followed by an addition of an equal volume of 
RSB buffer containing 0.2% NP-40 for another 10 minutes on ice. Nuclei were pelleted by 
centrifugation at 3000rpm for 10 minutes at 4°C. After centrifugation, the nuclei were lysed in ChIP 
lysis buffer and samples were sonicated on ice, five times for 10 seconds, using a Cellai Soniprep 150 
on full power (amplitude = 24-26 microns). Immunoprecipitations were performed using rabbit 
polyclonal anti topoisomerase I antibodies (Abcam) and mouse monoclonal anti-Orc2p antibodies 
(Stressgen) with the aid of the Chromatin immunoprecipitation assay kit as described by the 
manufacturer. Competitive PCR analysis was performed as described above (section 2.6). 
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HeLa cells synchronized at the late G1 - G1/S border were incubated first with 1M CPT for 1 
minute and immediately after subjected to protein-protein cross-linking with DSP 100μg/ml (Lomant’s 
reagent, Pierce) still in the presence of 1M CPT. The cells were then washed twice with PBS 
containing 1M CPT, lysed with a solution of 1% sarkosyl in TE pH8 and the lysates were layered on 
top of a CsCl solution, 1.5 g/ml density. The samples were centrifuged at 70000rpm for 5 hours at 20ºC 
in a Beckman L8-70M Ultracentrifuge in order to separate the bulk DNA and protein-DNA complexes 
(bottom fraction) from free proteins (top fraction). The cellular DNA was collected, washed twice in 
TE buffer pH8 and twice in restriction enzyme buffer. The DNA was incubated with 100U of BstNI 
restriction enzyme for one hour at 37°C, washed three times in TE buffer pH8 and dissolved in ChIP 
lysis buffer. Chromatin immunoprecipitation using rabbit polyclonal anti topoisomerase I antibody 
(Abcam) and mouse monoclonal anti-Orc2p (Stressgen) was performed using the Chromatin 
immunoprecipitation assay kit as described by the manufacturer. The immunopurified DNA was 
isolated, following proteinase K treatment, by phenol/chloroform/isoamyl alcohol extraction followed 
by ethanol precipitation. This DNA was used as a substrate for a simultaneous PCR amplification of 
two DNA fragments using 3 sequence specific primers: D1, E1 and T1 (for D1, E1 sequence and 
genomic position see table 2.2.1, primer T1 5’ GGTTCTGCCTCTGAGTTTATTCCTGAGG 3’, 
genomic position 3984-4011, corresponding to GeneBank accession number M94363). The PCR 
reaction contained 5l 10x Taq polymerase buffer, 4l 25mM MgCl2, 1l (10pmol) D1, 1l (10pmol) 
E1, 1l (10pmol) T1, 1l dNTPs (10mM each), 0.25l Taq polymerase (2U/l) (Promega), 5l 
immunopurified DNA and H2O up to 50l. The amplification conditions used were the following: 





2.8.2 Topoisomerase II. 
 
HeLa cells synchronized in the middle of G1 were incubated first with 10nM VP16 for 1-10 
minutes and immediately after subjected to protein-protein cross-linking with DSP as in the above 
experiment. Chromatin immunoprecipitation using goat polyclonal anti-topoisomerase II antibody 
(Santa Cruz) and mouse monoclonal anti-Orc2p antibody (Stressgen) was performed using the CHIP 
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assay kit as described above. Immunoprecipitated DNA was purified and analyzed by TDPCR as 
described in section 2.3. 
 
2.9 In vitro DMS treatment.  
 
Asynchronous growing HeLa cells were lysed in buffer A and incubated overnight at 37°C. 
Total genomic DNA was isolated by phenol extraction and ethanol precipitation and resuspended in 
20l H2O. The DNA was incubated for 5 minutes with DMS (Sigma) 1% final concentration at room 
temperature. The reaction was stopped with 2 volumes of 1.5M sodium acetate, 1M -mercaptoethanol, 
the DNA was precipitated with ethanol and the pellet was resuspended in 100l piperidine (Sigma) and 
incubated at 95°C for 30 minutes. The sample was then frozen in dry ice and lyophilized in a Heto 
DNA Plus speedvac. The resulting pellet was resuspended in 50l H2O, frozen in dry ice and 
lyophilized again three times. Finally the DNA was resuspended in 50l H2O and used for LMPCR 
amplification as described above (section 2.2). 
 
2.10 Western blot analyses 
 
 In order to check antibody specificity, Western blots were performed after immunoprecipitation 
with the CHIP assay kit. The IP products was run on a 10% SDS-PAGE, the proteins transferred to a 
Optitran BA-S 85 reinforced nitrocellulose membrane (Schleicher & Schuell) using a Hoefer Semiphor 
(Amersham) system according to the manufacturer’s instructions. The membrane was blocked 
overnight at 4°C with SuperBlock® Blocking Buffer in PBS (Pierce). The membrane was then 
incubated with the primary antibody, diluted in PBS, for 1 hour, followed by 6 washes in PBS (1.5 
hours in total).  The secondary antibody, diluted in PBS, was added for another 30 minutes and the 6 
washes with PBS were repeated. The SuperSignal® West Femto Maximum Sensitivity Substrate 
(Pierce) was used for signal detection. The antibody dilutions were as follows: topo I and topo II 
primary 1:10000, secondary (Pierce) 1:20000, Orc2 primary 1:20000, secondary (Pierce) 1:7000.  
 
2.11 Mapping of topo I in vitro. 
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A 216 bp PCR fragment containing the lamin B2 origin was amplified using primers D3 and E3 
(see table 2.2.1). The PCR reaction mixture contained 5l 10x Taq polymerase buffer with 15mM 
MgCl2, 4l 25mM MgCl2, 1l (10pmol) of each primer, 1l dNTPs (10mM each), 5l genomic DNA 
(100ng/l), 0.25l Taq polymerase (2U/l) (Promega) and H2O up to 50l. The amplification product 
was then purified by PAGE, the DNA was extracted overnight from the gel by incubation in H2O at 
37°C, precipitated with ethanol and resuspended in H2O. 20ng of origin fragment were incubated with 
1U of human recombinant topo I (Sigma) in 10mM Tris pH7.4, 50mM NaCl, 5mM MgCl2, 0.1mM 
DTT, 100 g/ml BSA for 15 minutes at room temperature and with 1M CPT, 10M CPT-7[CH2-
Tris] or M gimatecan for another 5 minutes.  CPT-7[CH2-Tris] and gimatecan were synthesized 
according to published protocols by Sotir Zahariev (Dallavalle et al., 2001 and Wadkins et al., 2004). 
The reaction was stopped by addition of SDS 2% final concentration. Topo I was digested with 
200g/ml Proteinase K overnight, the DNA was purified by phenol/chloroform/isoamyl alcohol 
extraction and ethanol precipitation and resuspended in 20l of water. The topo I cleavage was mapped 
by the hot extension reaction (the final step in LM and TDPCR, see section 2.2) 
 
2.12 Mapping of topo II in vitro. 
 
The D3/E3 PCR fragment, 20ng (see above), was incubated first with 5U-25U of human 
recombinant topo II (USB) in 10mM Tris pH7.9, 50mM NaCl, 50mM KCl, 5mM MgCl2, 0.1mM 
EDTA, 15g/ml BSA, 1mM ATP for 10 minutes at room temperature and 5 minutes more with VP16, 
100M final concentration. The reaction was stopped with SDS 2% final concentration. Topo II was 
digested overnight with 200g/ml Proteinase K, the DNA purified by phenol/chloroform/isoamyl 
alcohol extraction and ethanol precipitation and hot extension was performed as above. 
    
2.13 In vitro complex formation.  
 
Dignam HeLa 0.4M nuclear extract 50g (Cilbiotech) was incubated in 22.5mM HEPES pH7, 
1mM Tris pH7.5, 0.2mM EDTA, 5mM MgCl2, 20mM KCl, 1mM ATP, 1mM DTT, 8% glycerol with 
20g of each competitor: poly (dA-dT)-poly(dA-dT) and poly(dG-dC)-poly(dG-dC) (Amersham) at 
room temperature for 20 minutes. In the case of Trichostatin A treatment, the mixture was incubated in 
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the presence of 100ng/ml TSA for 1 hour at room temperature instead of 20 minutes. Afterwards, 20ng 
of origin DNA was added for another 30 minutes. The reaction was stopped with SDS 2% final 
concentration or EDTA 50mM final concentration. Alternatively the complex was treated for a further 
5 minutes with 100VP16, then the reaction was stopped with SDS 2% final concentration. Proteins 
were digested overnight with 200g/ml Proteinase K while the DNA purification and hot extension 
were performed as above (section 2.7).  
For mapping the border of the in vitro complex, 50U  exonuclease (New England Biolabs) 
were added to the preformed complex, incubated at 37°C for 3 hours and then stopped with 2% SDS 
final concentration. The DNA was then purified and subjected to hot extension as described above. 
For the topo II immunoprecipitation experiment, the pre-formed protein complex on origin 
DNA was treated with 100VP16 for 5 minutes and the reaction was stopped by the addition of an 
equal volume of 2x lysis buffer for ChIP (2%SDS, 20mM EDTA, 100mM Tris HCl pH8.1). Chromatin 
immunoprecipitation using a goat polyclonal anti-topoisomerase II antibody (Santa Cruz) was 
performed using the Chromatin immunoprecipitation assay kit as described by the manufacturer. The 
immunopurified DNA was isolated by proteinase K treatment, phenol extraction and ethanol 
precipitation and subjected to TDPCR analysis as described above (section 2.3). 
 
 
2.14 Construction of mutated PCR fragments.  
 
Primers used to obtain mutated D3/E3 PCR fragments 1, 2 and 3: 
 
Mut1A: 5’ CAGCGCCAGGCCAATGATTTGTAATATACATTTTATGACTGG 3’,  
Mut1B: 5’ GAACACGCTAGGCATGCATCTTC 3’,  
Mut2A: 5’ CAGCGCCAGGGTACAACACTCCAATAAACATTTTGATTTTAGG 3’,  
Mut2B: 5’ CCAGTCATAAAATGTATATTACAAATCATTGG 3’,  
Mut3A: 5’ CTCCAATAAACATTTTGATTTTAGGTTCTGCCTCTG 3’,  
Mut3B: 5’ GCGCTGACAAAAAAGTTTCCAGTCATAAATGTATATTAC 3’ 
 
 61 
The PCR reaction mixture contained: 5l 10x Vent Exo- buffer, 1.5l 100mM MgSO4, 1l 
(10pmol) of each primer, 1l dNTPs (10mM each), 5l D3/E3 PCR product (0.1ng/l), 0.5l Vent 
Exo- (2U/l) and H2O up to 50l. 
The amplification conditions are as follows.  For primers Mut1A/E3bio:  95°C 5 minutes, (95°C 
30 seconds, 60°C 30 seconds, 76°C 1 minute) cycled 10 times, (95°C 30 seconds, 72°C 30 seconds, 
76°C 1 minute) cycled 25 times, 76°C 5 minutes. For primers Mut1B/D3bio:  95°C 5 minutes, (95°C 
30 seconds, 70°C 30 seconds, 76°C 1 minute) cycled 35 times, 76°C 5 minutes. For primers 
Mut2A/E3bio: same as Mut1A/E3bio.  For primers Mut2B/D1bio: 95°C 5 minutes, (95°C 30 seconds, 
60°C 30 seconds, 76°C 1 minute) cycled 35 times, 76°C 5 minute. For primers Mut3A/E3bio: same as 
Mut1A/E3bio. For primers Mut3B/D3bio: same as Mut1B/D3bio.  
For each mutation two PCR fragment were amplified using Vent Exo- as a polymerase in order 
to obtain blunt ends, each fragment having one of the 5’-ends blocked with a biotin tag.  The fragments 
were purified by PAGE and subsequently on Streptavidin Paramagnetic Beads (Promega) according to 
the manufacturer’s instructions. The fragments were detached from the beads by boiling at 95°C for 5 
minutes in 0.1% SDS, reannealed in a PCR machine, precipitated with ethanol and resuspended in 10l 
H2O. The two fragments were incubated together overnight at 4°C in a 50l ligation mixture 
containing: 23l PEG-40, 10l of each purified PCR fragment, 5l 10x T4 DNA ligase buffer and 2l 
T4 DNA ligase (400U/l) (New England Biolabs). The ligation products were purified by 
phenol/chloroform/isoamyl alcohol extraction and ethanol precipitation and used for PCR amplification 





3.1 Mapping of the interaction of topoisomerases I and II with the lamin B2 origin in asynchronous 
cells. 
 
3.1.1 Topoisomerase I. 
 
 In order to detect a possible interaction of topoisomerase I with the lamin B2 origin of DNA 
replication, the anti-cancer drug camptothecin was used. CPT is a topo I specific poison which 
reversibly inhibits the religation step in the catalytic cycle of topo I, leaving the enzyme covalently 
trapped on the DNA. The free 5’end of the DNA nick, introduced by topo I, can be mapped by LMPCR 
amplification, thus revealing the topo I cleavage position with nucleotide resolution. A schematic 
diagram of the method used to map the topo I-DNA cleavage complexes is shown in figure 3.1.1.1. 
Asynchronous growing HeLa cells at 60-70% confluence were incubated for 1 minute in 
complete medium supplemented with 1M CPT, then washed twice with warm PBS containing 1M 
CPT. All liquid was removed and the cells were lysed in a lysis buffer supplemented with 1M CPT to 
avoid reversal of the cleavage. Total cellular DNA was isolated, after proteinase K treatment of the 
lysate, by phenol/chloroform/isoamyl alcohol extraction followed by ethanol precipitation and 
resuspended in 20l of H2O. The free 5’ ends of the DNA were phosphorylated with T4 polynucleotide 
kinase and ATP in order to make them amenable to LMPCR amplification and the DNA was 
reprecipitated and resuspended in 20l of 0.1x TE buffer pH 7.4. 4l of DNA were used to perform the 
LMPCR amplification for the detection of the CPT stabilized topo I induced cleavable complex and the 
results are shown in figure 3.1.1.2. 
 In the presence of CPT two topo I induced single stranded breaks are found, on the upper and 
lower strand respectively, in the origin area covered by the replicative complexes. The exact position of 
the cuts is between nucleotides 3890 and 3891 on the upper strand and between nucleotides 3956 and 




Figure 3.1.1.1 - Mapping of the topoisomerase I-DNA cleavage complexes – experimental 
outline. HeLa cells were treated with 1M CPT for one minute in order to stabilize the topo I-DNA 
covalent complexes (left panel). The cells were then lysed, the total genomic DNA was isolated and 
used for ligation mediated PCR (LMPCR) analysis (right panel). In order to perform LMPCR analysis, 
the 5’ end of the DNA must be phosphorylated, therefore the genomic DNA was subjected first to an in 
vitro phosphorylation reaction. As a first step in LMPCR a sequence specific primer was annealed to 
the region of interest and extended in order to obtain a double stranded DNA blunt end, which, in turn, 
was ligated to an asymmetric linker. The next step was a PCR amplification of the substrate using a 
second sequence specific primer and a primer complimentary to the linker sequence. As a final step, a 
third sequence specific primer, radioactively labeled, is used for hot extension and the product is then 





Figure 3.1.1.2 - In asynchronous 
HeLa cells topoisomerase I cleaves the 
region of the lamin B2 origin which is 
covered by the replicative complexes. On 
both the upper and lower strand, 
respectively, one LMPCR stop 
corresponding to one CPT stabilized topo I 
cleavage complex can be detected. These 
stops correspond to the DNA 5’ end arisen 
from the topo I action at the origin. The 
black bars indicate the origin area covered 
by a protein footprint in asynchronous HeLa 
cells. Lanes 4,8 – cells treated with 1M 
CPT for one minute. Lanes 3,7 - cells 
treated with 1M CPT for one minute, 
washed from the drug and released for 5 
minutes in complete medium. Lanes 2, 6 – 
cells treated with DMSO only. G – In vitro 
DMS treated genomic DNA. 
 
Figure 3.1.1.3 - The position of the topoisomerase I cleavage sites at the lamin B2 origin in 
asynchronous HeLa cells. 
 
 
These cleavages lie very close to the position of the start-sites of bi-directional DNA synthesis, 
which correspond to nucleotide 3990 for the lower strand and 3993 for the upper strand, and are located 
on the strands template for leading strand synthesis. Figure 3.1.1.3 illustrates the position of the topo I 
cutting sites in relationship with the position of the start-sites of DNA synthesis. 
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These breaks are not detected when the cells are only treated with DMSO, the solvent used for 
CPT. Furthermore, when the cells are treated in the same manner with gimatecan, a CPT derivative 
which has a different electronic structure, the same cleavage can be detected, by LMPCR analysis, on 
the lower strand (figure 3.1.1.4). This proves that the position of the topo I cut is determined by the 
enzyme and is independent of the drug used to stabilize the cleavage complex. 
The CPT frozen topo I cleavable complexes are quickly and fully reversible. Upon drug 
removal and incubation of the cells for 5 minutes in complete medium both the upper and lower strand 
cuts disappear when LMPCR analysis of the origin area is performed (see figure 3.1.1.2). 
 Nonetheless, CPT is a very efficient anti-cancer drug and its cytotoxicity is mainly due to the 
formation of replication dependent double stranded breaks (DSBs) when a replication fork collides 
with a stabilized topo I-DNA cleavable complex (Hsiang et al., 1989 and Ryan et al., 1991). Also, these 
DSBs lead to the phosphorylation of histone H2AX which in turn induces the recruitment of the 
Mre11-Rad50-Nbs1 (MRN) complex involved in the repair of DNA damage (Furuta et al., 2003).  
Therefore CPT probably activates a variety of checkpoints inside the cell by its action on topo I 
and, even though the time of CPT treatment used for the above experiments was very short (only one 
minute) at a low drug concentration of 1M, there still a possibility that the single stranded breaks 
detected by LMPCR are due to a side effect of the CPT treatment. In 
order to rule out a possible disruption of the interaction of the 
replicative complex with the origin upon CPT treatment, a 
photofootprinting analysis of the origin region was performed in the 
presence and absence of CPT. 
 
 
Figure 3.1.1.4 - The effect of gimatecan on the formation of 
the in vivo topo I cleavable complex. The position of the topo I 
cutting site is not influenced by the drug used to stabilize the topo I-
DNA covalent complex.  Lane 2 – cells treated with 1M CPT. Lane 
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Photo-footprinting is an alternative method to chemical 
footprinting which has the advantage of highlighting both the 
protein-DNA interactions as well as the DNA conformation within 
a region. Asynchronous growing HeLa cells treated or not with 
1M CPT, as in the above experiments, were washed with PBS 
supplemented or not with 1M CPT and, after removal of all 
liquid, they were irradiated directly in the Petri dishes with one 
femtosecond pulse of two wavelengths (266nm and 400nm) 
coming from a femtosecond UV laser source. The cells were lysed 
immediately after irradiation, the DNA was isolated as before and 
TDPCR analysis was performed (see figure 3.1.2.1 for an outline 
of the TDPCR procedure). The resulting pattern of DNA damage 
detected at the origin (the footprint) represents a combination of 
UV DNA damage and protein-DNA crosslinks and gives an 
overall image of the DNA conformation in this region. The results 
are presented in figure 3.1.1.5. 
Figure 3.1.1.5 - Photofootprinting analysis of the lamin B2 
origin area in asynchronous cells treated or not treated with CPT. 
The band which appears after CPT treatment corresponds to the 
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A comparison of the overall footprint in the cells treated or not with CPT reveals no significant 
change over a region of 500bp containing the origin, with the exception of a prominent band which 
appears after CPT treatment on both upper and lower strand. This band corresponds to the previously 
detected LMPCR stop arisen from the inhibition of the topo I religation step and the consequent 
stabilization of the DNA single stranded break. 
Therefore treatment with CPT does not alter the existing protein-DNA interactions at the origin 
in a significant manner. 
 
3.1.2 Topoisomerase II. 
 
For the detection of an interaction of topoisomerase II with the lamin B2 origin of DNA 
replication, another anti-cancer drug was used, etoposide or VP16, a poison specific for topo II. Similar 
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to CPT, VP16 reversibly inhibits the religation step in the topo II catalytic cycle, leaving the enzyme 
covalently trapped on the DNA. In contrast to topo I, topo II becomes covalently attached to the 5’end 
of the DNA, and, as a consequence, it is impossible to use LMPCR amplification for the detection of 
this type of cleavage. To circumvent this problem, TDPCR was used, a procedure very similar to 
LMPCR which is insensitive to the state of the 5’ end of the DNA. A schematic diagram of the method 
used to map the topo I-DNA cleavage complexes is shown in figure 3.1.2.1. 
Asynchronous growing HeLa cells were incubated for 1 minute in complete medium 
supplemented with 10nM VP16 and then washed twice with PBS containing 10nM VP16. All liquid 
was removed and the cells were lysed in a lysis buffer supplemented with 10nM VP16. Total cellular 
DNA was isolated, after proteinase K treatment of the lysate, by phenol/chloroform/isoamyl alcohol 
extraction followed by ethanol precipitation and resuspended in 20l of 0.1x TE buffer pH 7.4. 4l of 
DNA were used to perform the TDPCR amplification for the detection of the topo II DNA cleavages. 
The results are shown in figure 3.1.2.2. 
Topo II cleaves the origin, inside the area covered by the replicative complexes, in a manner 
similar to topo I: two single stranded cuts are observed, on the upper and lower strand respectively, 
close to the start-sites of DNA replication. The precise position of these cleavages is between 
nucleotides 3914 and 3915 on the upper strand and between nucleotides 3940 and 3941 on the lower 
strand, on the strands template for leading strand synthesis. Figure 3.1.2.3 illustrates the position of the 




Figure 3.1.2.1 - Mapping of the topoisomerase II-DNA cleavage complexes – experimental 
outline. HeLa cells were treated with 10nM VP16 for one minute in order to stabilize the topo II-DNA 
covalent complexes (left panel). The cells were then lysed, the total genomic DNA was isolated and 
used for terminal transferase dependent PCR (TDPCR) analysis (right panel). As a first step a sequence 
specific primer was annealed to the region of interest and multiple rounds of polymerase extension 
were performed. The extension products, thus obtained, were subjected to 3’end ribotailing using 
terminal transferase (TdT) and riboG. This ribonucleotide is not the preferred substrate for TdT and 
under determined conditions the enzyme is able to add only 3 nucleotides (on average). The three 
riboGs are complimentary to an overhand of three C residues contained in the asymmetric linker, which 
aides the linker ligation reaction. The next step involves PCR amplification of the substrate using a 
second sequence specific primer and a primer complimentary to the linker sequence. As a final step, a 
third sequence specific primer, radioactively labeled, is used for hot extension and the product is then 
visualized, following sequencing gel electrophoresis, by autoradiography.  
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Figure 3.1.2.2 - In asynchronous HeLa 
cells topoisomerase II cleaves the region of the 
lamin B2 origin which is covered by the 
replicative complexes. On both the upper and 
lower strand, respectively, one TDPCR stop 
corresponding to one VP16 stabilized topo II 
cleavage complex can be detected. These stops 
correspond to the DNA 5’ end arisen from the 
topo II action at the origin. The black bars 
indicate the origin area covered by a protein 
footprint in asynchronous HeLa cells. Lanes 4,8 
– cells treated with 10nM VP16 for one minute. 
Lanes 3,7 - cells treated with 10nM VP16 for 
one minute, washed from the drug and released 
for 5 minutes in complete medium. Lanes 2, 6 – 
cells treated with DMSO only. G – In vitro 
DMS treated genomic DNA. 
 
Figure 3.1.2.3 - The position of the 
topoisomerase II cleavage sites at the lamin B2 
origin in asynchronous HeLa cells. 
As expected these cleavages are not detected when the cells are treated with DMSO in the 
absence of the topo II poison. Furthermore the VP16 stabilised topo II cleavage complexes are fully 
reversible; if the cells are washed from the drug and incubated in complete medium for 5 minutes no 
cleavage can be detected by TDPCR analysis on either origin upper or lower strands. 
 In order to ensure that the treatment with VP16 has not disturbed the pre-existing protein-DNA 
interactions in the origin area, a photofootprinting analysis was performed in the presence and absence 
of the anti-cancer drug. As in the case of the photofootprinting controls for CPT treatment, the cells 
were treated or not with VP16, washed with PBS with or without drug addition and, after complete 
3881                      3891                     3901                    3911                    3921                   3931                     3941                   3951                    3961 
  
                                                                                                                          
GATGCATGCC   TAGCGTGTTC    TTT TTT TT TT   CCAATGATTT   GTAATATACA   TTTTATGACT    GGAAACTTTT   TTGTACAACA   CTCCAATAAA 







G   –   +  + VP16 
 1      2      3      4 
Lower strand 
 G  –  +  + 
  5      6     7      8 
Upper strand 
 71 
removal of all liquid, they were irradiated directly on the Petri dishes with one femtosecond pulse of 
two wavelengths (266nm and 400nm) coming from a femtosecond UV laser source. The results are 
displayed in figure 3.1.2.4. 
Comparison of the footprinting pattern obtained by TDPCR analysis of a 500bp region 
containing the lamin B2 origin shows no significant difference, on both upper and lower strands, 
between the VP16 treated or untreated samples, with the exception of one major band present after 














Figure 3.1.2.4 - Photofootprinting analysis of the lamin B2 
origin area in asynchronous cells treated or not treated with VP16. 
The band which appears after VP16 treatment corresponds to the 
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3.2 Mapping of the interaction of topoisomerases I and II with the lamin B2 origin in synchronized 
cells. 
 
3.2.1 Topoisomerase I. 
  
In order to establish in which phases of the cell cycle topoisomerase I interacts with the origin, 
HeLa cells were synchronized in M, G1, G1/S and S phases of the cell cycle, treated with 1M CPT for 
one minute and lysed as for the experiments involving asynchronous cells. For cell synchronization 
three different drugs were used: nocodazole in order to obtain M phase cells, a drug which inhibits 
microtubule polymerization, mimosine for late G1 - G1/S border cells, a strong iron chelator which is 
thought to inhibit ribonucleotide reductase and therefore lower intracellular dNTP pools, and 
aphidicolin for G1/S border - early S cells, a DNA polymerase inhibitor. The DNA was isolated and 
LMPCR was performed for the upper and lower strand of the origin region using the same primers 
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which allowed the detection of the topo I cutting sites in asynchronous HeLa cells. The results are 
shown in figure 3.2.1.1. 
In synchronized cells topo I introduces single-stranded nicks in both the origin upper and lower 
strand in M phase, very early G1 and late G1 - G1/S border. The position of these cleavages coincides 
with the position of the two cleavages mapped in asynchronous growing HeLa cells.   
With the aim of further characterizing the dynamic relationship of topoisomerase I with the 
origin, the surrounding region was also analyzed by LMPCR. Different primer sets were used to 
explore both the upper and lower strand, to the left and to the right of the origin, for an extended 
analysis of 1500bp (for the position of the primers see figure 3.2.1.2). Since human topo I seems to be 
involved in many aspects of DNA metabolism which might not be necessarily connected with DNA 
replication, this supplementary LMPCR analysis in synchronized HeLa cells provides a better picture 
of the topological requirements for topo I activity in this region. 
The results, illustrated in figure 3.2.1.2, show that topo I function appears to concentrate at the 
origin since in the region immediately adjacent the enzyme does not cleave the DNA. There is, 
however, one exception to this observation, namely a topo I cutting site, exclusively in the middle of S 
phase, approximately in the region of nucleotides 4335 to 4340, close to the promoter of the TIMM13 
housekeeping gene. It should be noted that the lamin B2 origin is an early firing origin with the peak of 
nascent DNA enrichment (as analyzed by competitive PCR) detectable in the first minutes of S phase. 
The TIMM13 promoter is cleaved by topo I after at least 1h of S, at which point the region would have 
already been replicated. In view of the fact that topo I is actively involved in transcription, this 















Lanes 2, 13 - 
M phase. 
Lanes 3, 14 - 
30 minutes of 
G1. Lanes 4, 15 - 1 hour of G1. Lanes 5, 16 - 5 hours of G1. Lanes 6, 17 - 7 hours of G1. Lanes 7, 18 - 
late G1 - G1/S border (mimosine). Lanes 8, 19 - G1/S border - early S (aphidicolin). Lanes 9, 20 - 1 
hour of S. Lanes 10, 21 - 5 hour of S. Lanes 11, 22 - 7 hour of S. G – In vitro DMS treated genomic 
DNA. 
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Figure 3.2.1.2 - Interaction of DNA topoisomerase I with the 1.5kb region surrounding the 
lamin B2 origin in synchronized HeLa cells. Primer sets D and E are the primers used to analyze the 
origin area (see figure 3.2.1.1). Primer set B allows the detection of a topo I cleavage site, on the lower 
strand, in the vicinity of the TIMM13 gene promoter. G – In vitro DMS treated genomic DNA. 
 
3.2.2 Topoisomerase II. 
 
An analysis of the behavior of topoisomerase II in synchronized cells has also revealed a 
dynamic interaction of this enzyme with the origin. HeLa cells were synchronized in M, G1, G1/S and 
S phases of the cell cycle, treated with 10nM VP16 for one minute, washed, lysed and the isolated 
DNA was analyzed by TDPCR as in the case of asynchronous cells. The results are shown in figure 
3.2.2.1. 
The upper and lower strand topo II cutting sites mapped at the origin in asynchronous growing 
cells were found to be present only in M phase and in the middle of G1. An additional TDPCR analysis 
was performed in the case of topo II as well, with the region surrounding the origin being investigated 
and the results reported in figure 3.2.2.2. For this analysis the same primers were used as in the case of 
topo I and a map with their position is found in figure 3.2.1.2.  
As in the case of topo I, the topo II activity appears to be concentrated at the origin with no 
cleavages being present outside this region apart from one cleavage site on the lower strand, between 
nucleotides 3727 and 3728. This position is over 200bp away from the origin topo II cutting sites and, 
it seems that, contrary to the origin cuts, this particular topo II-DNA interaction is constant throughout 
the cell cycle. Due to the difference in the behaviour of the two topo II molecules, at and outside of the 
origin, during the cell cycle, a logical supposition is that the two enzymes belong to two different 
nuclear topo II subsets involved in different processes.  









In M phase both topo I and topo II seem to be in contact with the origin DNA, however, it is not 








Figure 3.2.2.1 - Interaction of DNA topoisomerase II with the lamin B2 origin in synchronized 
HeLa cells. Topo II introduces single stranded cuts on both the origin lower and upper strands in M 
phase (lanes 1 and 15) and from 3 up to 7 hours of G1 with a peak in 5 hours of G1 (lanes 5-8 and 19-
22). G – In vitro DMS treated genomic DNA. 
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Figure 3.2.2.2 - Interaction of DNA topoisomerase II with the 1.5kb region surrounding the 
lamin B2 origin in synchronized HeLa cells. Primer sets D and E are the primers used to analyze the 
origin area in asynchronous cells. Primer set G allows the detection, on the lower strand, of the same 
origin topo II cleavage site as primer set D (*) along with a second topo II cleavage site far away from 





































3.3 Topoisomerase  – ORC interactions at the lamin B2 origin. 
 
3.3.1 Topoisomerase I. 
 
 Given the presence of the topoisomerase I enzyme at the origin at late G1 - G1/S border, a 
crucial moment for replicon initiation, it is appealing to assume that this interaction has a role in origin 
firing. Nonetheless the mere presence of a protein in this region does not automatically imply a role in 
DNA replication. In order to verify that indeed topo I is involved in origin regulation an interaction 
with other members of the pre-initiation complex should be proven.  
 The hOrc2p, member of the human origin recognition complex, has been shown to interact with 
the origin in both G1 and S phases of the cell cycle and its position on the DNA (only on the lower 
strand) was mapped with nucleotide resolution (Abdurashidova et al., 2003). In the middle of G1, Orc2 
is bound at the origin on the lower strand at nucleotide 3960 (as detected by UV laser DNA-protein 
crosslinking), while in S phase its position on the DNA is shifted 17bp towards the start-sites, at 
nucleotide 3943 (see figure 1.4.1 in introduction for a map of the known protein-DNA interactions at 
the lamin B2 origin). 
 The exact position of Orc2 in late G1 or at the G1/S border is not known but it is logical to 
assume that the protein is still in contact with the DNA, as the 6-subunit ORC was shown to be an 
essential element for origin activity (Mendez and Stillman, 2003). To confirm this assumption, a ChIP 
assay was performed in cells synchronized in late G1 - G1/S border using anti-Orc2 antibodies.  
 HeLa cells synchronized in M phase were subjected to a second block using mimosine, a plant 
amino-acid which has been shown to block human cells shortly before initiation of S phase (Krude, 
1999). Due to the lack of a precise estimation of the G1 time-point at which these cells are blocked, the 
synchronization with mimosine will be referred to as late G1 - G1/S border.  
 The synchronized cells were crosslinked with formaldehyde for 5 minutes, lysed, the DNA was 
sonicated and immunoprecipitation was performed with either anti-Orc2 or anti-topo I antibodies (as a 
positive control). The immunopurified protein-DNA covalent complexes were decrosslinked by heating 
for 5 minutes at 95C, the proteins were digested with proteinase K and the DNA was isolated by 
phenol/chloroform/isoamyl alcohol extraction followed by ethanol precipitation. In order to asses the 
abundance of origin and non-origin DNA, competitive PCR amplification was carried out for the B48 
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(origin) and B13 (non-origin) region. The relative abundance of B48 and B13 PCR products is shown 



















2 at the lamin B2 origin in late G1 - G1/S border. 
Formaldehyde crosslink of cells synchronized in late 
G1 - G1/S border, followed by ChIP using anti topo I 
or anti Orc2 antibodies and competitive PCR amplification of origin (B48) and non-origin (B13) DNA 
fragments demonstrates the presence of topo I (as a control) and Orc2 at the origin in this phase of the 
cell cycle. Western blot of increasing amounts of immunoprecipitate obtained with anti-Orc2 and anti-
topo I antibodies is shown in the upper right panels.  
 
 As expected both ChIP assays for hOrc2p and htopo I showed an enrichment in origin 
fragments after competitive PCR amplification. The difference between the B48:B13 ratio in the case 
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no stoichiometric estimation of the Orc2/topo I ratio on the DNA can be inferred from this experiment. 
It should be noted that the procedure involved no treatment with a topo I poison and therefore it 
reinforces the conclusion that CPT does not direct the topo I-DNA interaction but only interferes with 
the catalytic cycle of the enzyme.  
 Thus the Orc2p is indeed present on the DNA in late G1 - G1/S border and its precise position 
is most likely at one of the two binding sites previously mapped. Considering that on the lower strand 
the topo I cutting site overlaps one of these Orc2 binding sites and is close to the other (topo I cleaves 
nucleotides 3956/3957, while the two previously mapped Orc2 binding sites are at positions 3943 and 
3960), the question arises whether these two proteins are interacting.  
 In order to confirm this hypothesis an elaborate experiment was performed aimed at showing 
that Orc2 and topo I are interacting concomitantly with the topo I cleavage of the origin DNA. An 
outline of this experiment is shown in figure 3.3.1.2. The nature of the topo I cleavage with the enzyme 
being covalently bound to the 3’end of the DNA makes it impossible to perform LM or TDPCR 
amplification following immunoprecipitation of the topo I cleavable complex. Both these techniques 
can only map the 5’ end of the DNA break which will be lost during IP as it is not crosslinked to the 
enzyme. In order to circumvent this problem an alternative PCR amplification was devised based on 
the knowledge of the positions of the topo I cutting sites at the origin.  
 In a first instance the procedure was validated by a simple topo I immunoprecipitation 
experiment, performed after CPT treatment, followed by PCR amplification of the origin region. HeLa 
cells synchronized in late G1 - G1/S border with mimosine were treated for one minute with 1M CPT, 
washed twice with PBS containing 1M CPT, lysed with a solution of 1% sarkosyl in TE and loaded 
on top of a CsCl solution (1.5 g/ml density). The samples were centrifuged at 70000rpm for 5 hours, 
allowing the separation of the bulk DNA and protein-DNA complexes (bottom fraction) from free 
proteins (top fraction). The DNA fraction was collected and the origin region was liberated by 
restriction enzyme digestion. Anti-topo I antibodies were used to pull down the topo I-DNA cleavable 
complexes, the protein was digested with proteinase K and the DNA was purified by 
phenol/chloroform/isoamyl alcohol extraction followed by ethanol precipitation. 
 PCR amplification of the origin region was performed using three sequence specific primers 
chosen to amplify, simultaneously, a long (276bp) and a short (88bp) PCR fragment. The long PCR 
fragment contains both upper and lower strand topo I cleavage sites and is not amplifiable upon CPT 
treatment, while the short one is positioned adjacent and to the right of the lower strand topo I cutting 
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site. This makes it so that, upon CPT treatment and topo I IP, the substrate for the short PCR fragment 
is immunopurified, since it has the topo I enzyme covalently bound on its 3’ end.  
 The results of this experiment are reported in figure 3.3.1.2 and, as can be observed, if in the 
absence of CPT both PCR fragments are amplified in an equal manner, upon CPT treatment only the 
short fragment is detected after PCR amplification. Needless to say this experiment brings further proof 
that the DNA single stranded breaks detected after CPT treatment correspond indeed to topo I action. 
 Having developed a tool for the detection of the topo I DNA substrate immunopurified with the 
aid of anti-topo I antibodies, the possible interaction of Orc2 with topo I at the origin was investigated. 
HeLa cells synchronized in late G1 - G1/S border were treated for one minute with 1M CPT then 
treated for 5 minutes with dithiobis-(succinidylproprionate) (DSP or Lomant’s reagent), a protein-
protein crosslinking agent, still in the presence of CPT. The cells were washed twice with PBS 
containing 1M CPT, lysed and loaded on top of a CsCl solution (1.5 g/ml density). The samples were 
centrifuged at 70000rpm for 5 hours, the DNA fraction was collected and the origin region was 
liberated by restriction enzyme digestion of the DNA. Immunoprecipitation was performed with either 
anti-topo I or anti-Orc2 antibodies, the proteins were digested with proteinase K, the DNA was purified 
by phenol/chloroform/isoamyl alcohol extraction followed by ethanol precipitation and PCR 
amplification of the long and short fragment was carried out. 
 If the Orc2p is in close proximity of the topo I enzyme the two will be crosslinked to each other 
by DSP. Having already treated the cells with CPT means that topo I is covalently bound to the DNA, 
therefore IP with an anti-Orc2 antibody will pull down Orc2 linked to topo I which in turn is linked to 
the DNA. If Orc2 is not in close proximity to topo I they will 
not be crosslinked together and the immunoprecipitate 
obtained using the anti-Orc2 antibody will not contain any 
DNA. A 
schematic 
diagram of this 
experiment and 
the results 




                  
Figure 3.3.1.2 - Interaction of topoisomerase I 
with Orc2p at the lamin B2 origin in late G1 - G1/S 
border. PCR amplification of the origin region (gDNA – 
genomic DNA) was performed using three sequence 
specific primers (see the top right diagram for the 
position of the primers) in order to obtain a long 
(276bp) and a short (88bp) PCR fragment (lane 1). Due to the position of the 
primers, the long PCR fragment can be obtained only in the absence of CPT 
treatment, while the short product is insensitive to CPT action. 
Immunoprecipitation with anti topo I antibodies following CPT 
treatment of cells synchronized in late G1 - G1/S border allows the simultaneous purification of the 
DNA substrate used in the amplification of the short PCR fragment (lane 2). In the absence of CPT 
treatment, IP with anti topo I antibodies does not result in concomitant origin DNA purification (lane 
4). CPT treatment coupled with DSP protein-protein crosslinking, in cells synchronized in late G1 - 
G1/S border, followed by IP with anti Orc2p antibodies, leads to the simultaneous purification of the 
same DNA substrate used in the amplification of the short PCR fragment (lanes 5). Topo I co-
precipitates with Orc2 also in the absence of DSP crosslinking. Immunoprecipitation of Orc2p from 
HeLa nuclear extracts also pulls down topo I (lower right panel). 
 
 The Orc2 and topo I proteins are in fact interacting at the lamin B2 origin, IP with an anti-Orc2 
antibody pulls down DNA which can be used to amplify the short PCR fragment but not the long one. 
Notably treatment of the cells with either CPT or DSP does not result in origin DNA 
immunopurification by the anti-Orc2 antibody. 
 These results prove that topo I is a member of the origin binding complex at late G1 - G1/S 
border and that it interacts directly with the Orc2 member of the human ORC. 
 
3.3.2 Topoisomerase II. 
 
 Having established that topo I is a protein partner of Orc2 in the origin pre-replicative complex, 
the possibility that topo II might also interact with Orc2 was explored. As shown by the experiments 
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with synchronized cells, topo II cleaves the origin region in the middle of G1, a time point for which 
the Orc2 position on the DNA (at least on the lower strand) is known. The topo II lower strand 
cleavage site is only 19 nucleotides away from the Orc2 binding site (topo II cleaves nucleotides 
3940/3941, while Orc2 binds position 3960). Taking into account that topo II is a large enzyme (the 
molecular weight of topo II is 170kDa while that of topo II is 180kDa) it is conceivable to assume 
that the two proteins are almost in contact if bound to the same DNA molecule.  
 In order to prove this deduction, an experiment similar to the topo I-Orc2 crosslinking assay 
was used. The property of topo II of becoming covalently bound to the 5’end of the DNA break during 
its catalytic cycle means that TDPCR analysis can be used also after immunoprecipitation with an anti-
topo II antibody (the 5’end of the DNA will be immunopurified along with the topo II protein 
covalently attached to it).  
HeLa cells treated with 10nM VP16 for 1 minute were washed twice with PBS containing 
10nM VP16, lysed and loaded on top of a CsCl solution (1.5 g/ml density). The samples were 
centrifuged at 70000rpm for 5 hours, the DNA fraction was collected and the origin region was 
liberated by restriction enzyme digestion of the DNA. Immunoprecipitation was performed with anti-
topo II antibodies, the proteins were digested with proteinase K, the DNA was purified by 
phenol/chloroform/isoamyl alcohol extraction followed by ethanol precipitation and analyzed by 
TDPCR. As can be observed in figure 3.3.2.1, the DNA immunopurified with the anti-topo II 
antibody, shows on the origin lower strand a break at the same position as the previously mapped topo 
II lower strand cutting site. This is further proof that the topo II enzyme is indeed responsible for the 
DNA breaks detected after VP16 treatment.  
HeLa cells synchronized in the middle of G1 were treated for 1 minute with 10nM VP16 and 
then treated for 5 minutes with DSP in the presence of VP16, washed twice with PBS containing 10nM 
VP16, lysed and loaded on top of a CsCl solution (1.5 g/ml density). The samples were centrifuged at 
70000rpm for 5 hours, the DNA fraction was collected and the origin region was liberated by 
restriction enzyme digestion of the DNA. Immunoprecipitation was performed with either anti-topo II 
or anti-Orc2 antibodies, the proteins were digested with proteinase K, the DNA was purified by 
phenol/chloroform/isoamyl alcohol extraction followed by ethanol precipitation and TDPCR analysis 
was performed with a primer set which allows the detection of both origin and non-origin topo II 
molecules (see section 3.2.2). The results of this experiment are reported in figure 3.3.2.2. 
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In the middle of G1 topo II and Orc2 are in close proximity at the lamin B2 origin, seeing that 
they can be crosslinked by DSP. Upon combined treatment with VP16 and DSP, immunoprecipitation 
with anti-Orc2 antibodies pulls down a DNA fragment which contains a break at the same position as 
the topo II lower strand cleavage site. Notably the same anti-Orc2 antibody is not able to 
immunoprecipitate a DNA fragment which contains a break corresponding to the non-origin topo II 
cleavage site. This difference in protein partners is an additional piece of evidence towards the 
hypothesis that the origin and non-origin bound topo II molecules perform different functions on the 
DNA (see section 3.2.2).  
In brief, in the middle of G1, topo II is an ORC protein partner via its interaction with Orc2 and 








Figure 3.3.2.1 - Immunoprecipitation of the topoisomerase 
II enzyme covalently attached to the lamin B2 origin DNA. Upon 
VP16 treatment topo II is covalently crosslinked to the origin DNA 
(lane 3). Western blot of increasing amounts of immunoprecipitate 
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with Orc2p at the lamin 
B2 origin in the middle of G1. VP16 treatment coupled with DSP 
protein-protein crosslinking, in cells synchronized in the middle of 
G1, followed by immunoprecipitation with anti Orc2p antibodies, leads to the simultaneous purification 
of a DNA fragment which contains a break at the same position as the lower strand topo II cleavage 
(lane 10). The topo II molecule bound throughout the cell cycle outside of the origin (lanes 1-6) does 
not interact with Orc2. * - lower strand topo II cleavage site at the origin. ** - lower strand topo II 
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3.4 The role of topoisomerase I in lamin B2 origin activation. 
 
What is the role of topoisomerase I as a member of the origin binding complex at late G1 - 
G1/S border? Certainly right before origin firing modulation of DNA topology must be very important, 
but does topo I play a crucial role in this process? One way to investigate this issue would be to asses 
origin activity in the presence of CPT, having thus blocked the topo I activity. If the topo I relaxation 
activity represents an essential step in origin firing, then CPT treatment should abolish DNA synthesis. 
If instead topo I function is not absolutely required for initiation of DNA synthesis, then the presence of 
the blocked topo I molecules on the DNA will lead to the formation of double stranded breaks by a 
process called ‘replication run-off’.  
Pommier and colleagues have shown that upon CPT treatment of human colon carcinoma HT29 
cells they could detect the conversion of topoisomerase I cleavage complexes into replication mediated 
DNA double-strand breaks (Strumberg et al., 2000). This process was only detected on the leading 
strand of DNA synthesis and was due to the collision of a replication fork with a persistent single 
stranded break corresponding to the CPT stabilized topo I-DNA cleavable complex. They also 
observed that the extension of the nascent DNA strand occurred all the way to the DNA break leading 
to a double-stranded DNA blunt end, which could be in turn used as a substrate directly for the ligation 
step in LMPCR.  
LMPCR is a technique devised for mapping DNA breaks within a known region and differs 
from a normal PCR amplification in the fact that only one end of the DNA amplified is known. PCR 
amplification is achieved by using a sequence specific primer complimentary to the region analysed 
and a second primer complimentary to a linker molecule ligated to the DNA substrate which is being 
analyzed.  
When performing a LMPCR analysis in order to detect the 5’ end of the DNA break 
corresponding to a topo I covalent complex (the enzyme is attached covalently to the 3’ end of the 
nick), the first step involves the annealing of a sequence specific primer and polymerase extension up 
to the cleavage in order to obtain a double stranded DNA blunt end. This is in turn ligated to an 
asymmetric linker and PCR amplification is performed.  
The double-stranded DNA blunt end arisen from the replication run-off process is also 
amenable to ligation to the asymmetric linker and, thus, there is no need to perform the initial step of 
LMPCR, the extension from the sequence specific primer. This replication run-off property of 
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generating double stranded breaks can be exploited to distinguish between origin firing and non-firing 
upon CPT treatment. Figure 3.4.1 illustrates this concept.  
     
 
Figure 3.4.1 - The use of LMPCR in distinguishing between single and double stranded DNA 
breaks at the origin. The use of primer extension as a first step in LMPCR (left diagram) allows the 
formation of a double stranded blunt end which in turn allows the mapping if the 5’ end of the topo I 
single stranded cut. Upon origin firing (right diagram), the collision of the replication fork with the 
topo I single stranded cleavage results in the formation of a double stranded blunt end, removing 
therefore the need of the primer extension reaction.  
 
HeLa cells were synchronized by mimosine treatment in late G1 - G1/S border, washed from 
mimosine and released into S phase in the presence of 1M CPT for up to 30 minutes. The cells were 
then lysed, the proteins were digested with proteinase K and the DNA purified by 
phenol/chloroform/isoamyl alcohol extraction followed by ethanol precipitation. LMPCR analysis was 
performed, for both the upper and lower strand of the origin region, with or without the first step 
(namely the primer extension) in order to detect the corresponding DNA single or double stranded 
breaks derived from the topo I-DNA covalent complexes. The results are displayed in figure 3.4.2. 
The CPT stabilized topo I induced DNA nicks are not repaired up to 30 minutes if the drug is 
not removed from the cell medium. Both the origin upper and lower strand topo I DNA cleavages can 
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still be detected by regular LMPCR analysis after 30 minutes of cell incubation with CPT, and no 
difference in the intensity of the LMPCR stops is visible. This proves that DNA replication from the 
lamin B2 origin is severely impaired upon continuous CPT treatment, given the presence of persistent 
DNA breaks very close to the start-sites of DNA synthesis and on the strands template for leading 
strand synthesis.  
If the first step of LMPCR amplification is omitted (namely the primer extension) and the DNA 
substrate is subjected directly to the linker ligation step, no LMPCR stops are visible for the origin 
area. This indicates that, in this area, there are no double stranded DNA blunt ends which can be ligated 
to the LMPCR asymmetric linker. Considering that DNA synthesis might have been aborted before 
reaching the topo I nick, thus creating a staggered double stranded break, the same experiment was also 
performed including an initial polymerase end filling reaction in order to obtain the blunt end needed 
for the ligation step. Also in this case no LMPCR stops could be detected in the origin area confirming 
the fact that there is no region of double stranded DNA at the origin.  
As a control the same experiment was performed also in the presence of caffeine, an inhibitor of 
checkpoint response, since 30 minutes of CPT treatment might activate DNA replication checkpoints 
inside the cell and therefore inhibit replicon firing (Sarkaria et al., 1999). Even in this case no double 
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cleavage complexes at the lamin B2 origin do not lead to replication run-off. Cells synchronized in late 
G1 - G1/S border and released up to 30 minutes into S phase, in the presence of CPT, exhibit a single 
stranded DNA break (SSB) at the lamin B2 origin due to the persistence of the topo I-DNA covalent 
complexes (left side lower and upper strand gels). These topo I induced single stranded breaks are not 
transformed into double stranded breaks (DSB) by ‘replication run-off’ (top right side lower and upper 
strand gels). The single stranded breaks are detected by standard LMPCR analysis, while the double 
stranded breaks are mapped by performing an LMPCR analysis without the primer extension reaction 
step. In the event that the ‘replication run-off’ process did not yield double stranded DNA blunt ends 
but recessed ones, a polymerase end filling reaction was performed before linker ligation (bottom right 
side lower strand gel). The same results are obtained also when the cell cycle checkpoint activation is 
inhibited by caffeine treatment. 
 
This allows the conclusion that, in the presence of CPT, release of the cells in S phase is not 
accompanied by the firing of the lamin B2 origin. Nonetheless the method used in this experiment is 
based on the purification of a very short piece of double stranded DNA (the topo I cleavage sites are 
located only 41 and 26 nucleotides away from the upper and lower strand start-sites respectively). The 
possibility of melting these short double stranded molecules during the DNA purification step and, as a 
result, losing the substrate for the ligation reaction cannot be excluded.  
Consequently another method was used to validate these results. This experiment is based on 
the fact that if DNA synthesis is initiated in the presence of CPT then the nascent DNA can be labeled 
with bromodeoxyuridine (BrdU). However if the DNA synthesis is blocked no BrdU incorporation is 
possible. 
HeLa cells synchronized by mimosine treatment in late G1 - G1/S border were washed from 
mimosine and released into S phase in the presence of BrdU and 1M CPT for up to 30 minutes. 
Subsequently the cells were washed from both CPT and BrdU and released in complete medium for up 
to 10 minutes. This release step enables origin firing, since the topo I covalent complexes have the 
property of being completely reversible within a short time after drug removal. The cells were then 
collected, resuspended in PBS containing 10% glycerol and lysed in the wells of a 1.2% alkaline 
agarose gel immersed in alkaline running buffer. The gel was run overnight and the short nascent DNA 
was isolated from the gel. Competitive PCR analysis was performed in order asses the abundance of 
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origin (B48) and non-origin (B13) DNA before and after immunoprecipitation with anti-BrdU 
antibodies. The results are shown in figure 3.4.3. 
Origin firing during the CPT block leads to BrdU incorporation into the nascent DNA, but if the 
DNA synthesis starts only after reversal of the topo I-DNA covalent complexes, no BrdU incorporation 
is possible. Competitive PCR analysis of the abundance of origin and non-origin DNA shows that, even 
though the origin DNA is enriched after CPT treatment, there is no incorporation of BrdU in this 
sample. Therefore the origin has fired only after the reversal of the topo I cleavage complexes. This 
brings further proof to the initial observation that inhibition of topo I activity by CPT treatment 




















control. Mimosine does not allow entry into S phase. Middle panel -positive control. Upon mimosine 
removal cells enter S phase. Right panel - upon release into S phase in the presence of CPT the lamin 







3.5 Mapping of the interaction of topoisomerases I with the lamin B2 origin in vitro. 
 
 Type IB DNA topoisomerases have very degenerate cleavage consensus sequences (Capranico 
and Binaschi, 1998). However, considering the observed specific topoisomerase I interaction with the 
origin sequence in vivo, the affinity of the enzyme for this region was investigated in a series of in vitro 
reactions.  
A 216bp DNA fragment containing the lamin B2 origin of DNA replication was incubated with 
human recombinant topoisomerase I, at room temperature, for 15 minutes followed by the addition of 
CPT (1M final concentration) for a further 5 minutes incubation. The reaction was stopped by the 
addition of a strong denaturant (SDS), the DNA isolated by proteinase K treatment, 
phenol/chloroform/isoamyl alcohol extraction and ethanol precipitation and the topo I induced DNA 
breaks were mapped by hot extension. The results are shown in figure 3.5.1. 
Surprisingly the origin fragment does not exhibit a random cleavage pattern in the presence of 
topo I but displays only 5 specific cutting sites: four located on the upper strand (positions 3880-3881, 
3890-3891, 3897-3898 and 3924-3925) and only one located on the lower strand (position 3956-3957). 
Out of these, one of the four upper strand sites and the lower strand cleavage site are identical to the 
ones found in vivo. Most remarkably, on the lower strand, in a piece of DNA long 216bp, topo I is able 
to cleave just one site. This indicates that the enzyme has the ability to recognize specifically this 
region.  
As mentioned in section 3.1.1, the in vivo use of gimatecan instead of CPT does not affect the 
position of the topo I cleavage site on the lower strand. This is also true for experiments performed in 
vitro. When either gimatecan or CPT-7[CH2-Tris] (another CPT derivative) were used instead of CPT 
in order to stabilize the topo I-DNA covalent complex, the same topo I cutting site was detected on the 
lower strand (see figure 3.5.2). This reinforces the idea that the affinity of the enzyme for the region is 
the main factor which determines the choice of the cleaved bond. This is particularly important in the 
view of the fact that in the absence of a topo I poison no cleavages are detected at the origin. However, 
incubation of the DNA fragment with CPT in the absence of topo I does not result in DNA breakage 
(see figure 3.5.1), in good agreement with reports which emphasize the affinity of this drug for the topo 
I-DNA complex and not for either the enzyme or DNA alone (Pommier and Cherfils, 2005).  
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Figure 3.5.1 - Interaction of human 
recombinant DNA topoisomerase I with 
the lamin B2 origin in vitro. In the 
presence of 1M CPT topo I recognizes 
discrete sites in a DNA fragment 
containing the lamin B2 origin. G – In 
vitro DMS treated genomic DNA. * – 


















Figure 3.5.2 - The effect of 
gimatecan and CPT-7[CH2-Tris] on the 
in vitro formation of topoisomerase I 
cleavable complexes. The drug used to 
stabilize the topo I-DNA covalent 
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of the topo I cleavage. Lane 1 - 1M CPT. Lanes 2-4 – 1, 10, 50M CPT-7[CH2-Tris]. Lanes 7-9 – 1, 
10, 50M gimatecan. G – In vitro DMS treated genomic DNA. * – position of topo I cleavages present 




 In spite of the high affinity which topo I displays for the lamin B2 origin DNA in vitro, the five 
single stranded cutting sites mapped for the enzyme do not show a consensus DNA sequence. At least 
three of the upper strand cleavage sites lie very close to one another (8-10 nucleotides apart) and are 
most probably found on different DNA molecules. Furthermore, if the 6 nucleotides which contain the 
cleavage site are taken into account, all five cutting sites have unrelated sequences: GAA/GAT, 
GCC/TAG, GTG/TTC, TAA/TAT for the upper strand and GTT/GTA for the lower strand. This 
striking dissimilarity points towards a three dimensional DNA conformation recognition process, with 
apparent lack of sequence preference of the topo I enzyme. 
To substantiate this hypothesis three mutated DNA fragments were constructed and the ability 
of topo I to cleave these substrates was assessed. The results of this experiment can be found in figure 
3.5.3, while a map with all the mutated sequences and the corresponding cleavages is shown in figure 
3.5.4.  
In a first instance a stretch of 10 Ts (upper strand position 3901-3910) was replaced by a GC-
rich sequence: CAGCGCCAGG (mutation 1). This long T stretch is thought to be involved in vitro in 
the formation of a triplex structure at the origin (Kusic et al., 2005). Certainly the weak interactions 
between the two DNA strands in this region would give rise to a particular DNA conformation, which 
might influence the topo I DNA recognition. However, when the topo I cleavage assay was performed 
in the presence of this mutated fragment only the two cleavage sites close to the mutated region were 
lost (positions 3890-3891 and 3897-3898), with all the other cutting sites remaining unaltered.  
A second mutated DNA fragment involved the replacement of a 10 nucleotide sequence close to 
the lower strand topo I cleavage site. The AT-rich sequence AAACTTTTTT (upper strand position 
3943-3953), was replaced with the same GC-rich sequence CAGCGCCAGG (mutation 2). This change 
is also based on the supposition that the weak A-T hydrogen bonding in this region is important for the 
conformation adopted by the DNA fragment in vitro. Interestingly, in this instance, two of the topo I 
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cleavages are drastically reduced: the nearby lower strand cleavage (position 3956-3957) and one of the 
upper strand cleavages (position 3890-3891) situated far away from the mutated region.  
Finally, in a third mutated fragment, 6 nucleotides comprising the topo I lower strand cleavage 
site were changed from the original sequence of ACAACA (upper strand position 3955-3960) to the 
following GC-rich sequence: CAGCGC. This corresponds to a topo I cleavage site mutation from 
GTT/GTA to GTCGCG. In this case the lower strand topo I cutting site is completely abolished, while 




Figure 3.5.3 – The pattern of in vitro topo I cleavage sites in normal and mutated lamin B2 
DNA fragments. WT – normal, Mut1 – mutation 1, Mut2 – mutation 2, Mut3 – mutation 3 (see figure 
3.5.4 for sequences). G – In vitro DMS treated genomic DNA. * – position of topo I cleavages present 
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In conclusion topo I has a clear affinity for certain regions of the lamin B2 origin in spite of a 
lack of sequence consensus at the cleavage sites. The effect of DNA mutations seems to be restricted to 
the surrounding region with the observation that the lower strand cleavage site is sensitive to the 




Figure 3.5.4 - Map of the normal and mutated lamin B2 origin fragments. The mutated regions 
are highlighted. The position of the in vitro topo I-cleavable complexes are indicated by filled triangles.  












  3871                   3881                      3891                   3901                     3911                    3921                   3931                     3941                    3951                    3961 
 
 TTTTTAAGAA   GATGCATGCC   TAGCGTGTTC  CAGCGCCAGG  CCAATGATTT   GTAATATACA   TTTTATGACT    GGAAACTTTT   TTGTACAACA   CTCCAATAAA 





  3871                   3881                        3891                   3901                     3911                    3921                   3931                     3941                    3951                    3961 
 
 TTTTTAAGAA   GATGCATGCC    TAGCGTGTTC     TTT TTT TT TT   CCAATGATTT   GTAATATACA   TTTTATGACT    GGAAACTTTT    TTGTCAGCGC   CTCCAATAAA 





  3871                   3881                         3891                   3901                    3911                    3921                    3931                     3941                    3951                    3961 
 
 TTTTTAAGAA   GATGCATGCC     TAGCGTGTTC    TTT TTT TT TT   CCAATGATTT   GTAATATACA   TTTTATGACT    GGAAACTTTT   TTGTACAACA   CTCCAATAAA 








  3871                   3881                        3891                   3901                     3911                    3921                   3931                     3941                    3951                    3961 
 
 TTTTTAAGAA   GATGCATGCC    TAGCGTGTTC     TTT TTT TT TT   CCAATGATTT   GTAATATACA   TTTTATGACT    GGCAGCGCCA  GGGTACAACA  CTCCAATAAA 








3.6 Mapping of the interaction of topoisomerases II with the lamin B2 origin in vitro. 
 
 Human topoisomerases II (both  and  isoforms) share the topoisomerase I property of having 
a degenerate cleavage consensus (Capranico and Binaschi, 1998). When an in vitro cleavage assay was 
performed, using the same 216bp lamin B2 DNA fragment, the human recombinant topo II enzyme 
and VP16 as a poison, a random cleavage pattern of origin DNA was detected (see figure 3.6.1). This 
observation allowed the conclusion that, in contrast to topo I, topo II is not able to recognize 
specifically the lamin B2 origin fragment in vitro.  
 
Figure 3.6.1 - Interaction of human recombinant DNA topoisomerase II 
with the lamin B2 origin in vitro. In the presence of VP16 topo II introduces 


















Nevertheless, the precise in vivo localisation of the topo II enzyme on 
origin DNA might be influenced by other nuclear proteins. To further investigate 
Topo II  
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this possibility an in vitro assay was developed based on the assembly of a specific multi-protein 
complex on origin DNA.  
A Dignam HeLa nuclear extract, obtained from asynchronously growing cells, was pre-
incubated at room temperature with 100-fold excess of competitor DNA, poly(dA-dT)-poly(dA-dT) 
and poly(dG-dC)-poly(dG-dC), for 20 minutes, followed by a 30-minute incubation with the 216bp 
lamin B2 origin fragment (radioactively labeled). The whole reaction mix was then loaded on a 5% 
non-denaturing acrylamide gel, in a bandshift assay, in order to verify the formation of a protein 
complex on the origin DNA (illustrated in figure 3.6.2).  
 
Figure 3.6.2 - Nuclear proteins form a specific in vitro complex on a DNA fragment containing 
the lamin B2 origin. The bandshift assay allows the detection of a retarded band (corresponding to part 
of the origin DNA) in the presence of the 0.4M nuclear extract.  
 
 
After establishing a reproducible complex formation reaction, the incubation with the origin 
DNA was followed by the addition of the topo II poison VP16 (100M final concentration) for a 
further 5 minutes and the reaction was stopped by the addition of detergent (SDS). The DNA was 
purified by proteinase K treatment, phenol/chloroform/isoamyl alcohol extraction and ethanol 
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precipitation. The topo II induced DNA breaks were mapped by hot extension and the results are 
presented in figure 3.6.3. 
Remarkably in the presence of the Dignam nuclear extract the origin DNA exhibits two single 
stranded breaks, on the upper and lower strand respectively, which share the position of the in vivo 
mapped topo II cleavage sites.  
The in vitro origin complex occupies a precise region, as shown by  exonuclease protection 
assay. The pre-formed protein-DNA complex was subjected to  exonuclease digestion in order to 
detect its left and right borders. The DNA was further purified by proteinase K treatment, 
phenol/chloroform/isoamyl alcohol extraction and ethanol precipitation and the position of the upper 
strand left and lower strand right borders was mapped by hot extension. The results are shown in figure 
3.6.4. 
The region covered by the in vitro origin complex is similar to the region covered in vivo by the 
G1 pre-replication complex (as mapped by DMS footprinting). The upper strand left border is 
positioned at nucleotide 3851 and the lower strand right border is positioned at nucleotide 4007. The in 
vivo DMS footprint in the middle of G1 covers a similar region with the same lower strand border but 
with a much reduced area protected on the upper strand (see figure 3.6.4). This is in good agreement 
with the fact that the Dignam nuclear extract used to build the in vitro complex comes from 
asynchronous growing cells, the majority of which are in the G1 phase of the cell cycle. 
An immunoprecipitation experiment using an anti-topo II antibody was able to pull down the 
topo II enzyme covalently linked to the origin DNA, following the formation of the in vitro protein 
complex (see figure 3.6.3). The Dignam nuclear extract, pre-incubated with 100-fold excess of 
competitor DNA for 20 minutes, was incubated for another 30 minutes with the origin fragment and an 
additional 5 minutes with VP16. Anti-topo II antibodies allowed the purification of the enzyme 
covalently bound to the 5’ end of the DNA break, the DNA was further purified by proteinase K 
treatment, phenol/chloroform/isoamyl alcohol extraction and ethanol precipitation and the position of 
the DNA breaks was mapped by TDPCR analysis.  
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Figure 3.6.3 - Interaction of DNA topoisomerase II with the lamin B2 origin in vitro, as part of 
an origin specific protein complex. Topo II is helped by other nuclear proteins in recognizing 
specifically the lamin B2 origin DNA. The topo II – DNA covalent complex can be stabilized by VP16, 
SDS or EDTA treatment. Lanes 4, 11 – mutated origin fragment (mutation 2, see figure 3.5.4 for 
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sequence). Lane 6 - immunoprecipitation with anti-topo II antibodies confirms the presence of the 
topo II enzyme on the DNA.  * – position of topo I cleavages present also in vivo. G – In vitro DMS 
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Figure 3.6.4 - Comparison between the position of the in vitro origin complex and the in vivo 
pre-replicative complex. The upper strand left border and the lower strand right border (dashed arrows) 
were mapped for the in vitro origin specific complex by  exonuclease protection assay (lanes 1 and 5). 
The sequence covered by the in vitro formed complex is similar to the region covered in vivo by the 
origin binding complex in the middle of G1, as previously mapped by DMS footprinting 
(Abdurashidova et al., 1998). G – In vitro DMS treated genomic DNA. * – position of topo II cleavages 
present in vivo and in vitro. 
 
The DNA single stranded breaks obtained after the incubation of the origin fragment with the 
HeLa nuclear extract are indeed due to topo II action.  
Furthermore, these two breaks are not dependent upon VP16 treatment, as indicated in figure 
3.6.3. Treatment with a strong denaturant, namely SDS, is sufficient for stabilizing these DNA nicks. 
Addition of a chelating agent, EDTA, is also sufficient to stabilize the topo I-DNA covalent complex. 
These results indicate that the topo II cleavage reaction is sensitive to both denaturing conditions and 
Mg
2+
 availability. They also highlight the fact that VP16 has no influence over position of the topo II 
cleavage sites. 
The fact that topo II does not recognize by itself the lamin B2 origin DNA is also supported by 
evidence that, when a mutated origin fragment (mutation 2, see section 3.5 and figure 3.5.4) is used to 
build the in vitro origin complex, the position of the topo II cleavages is not changed. Mutation 2 is 
located just 2 nucleotides away from the topo II lower strand cleavage site but it does not affect the 
ability of the enzyme to cleave the DNA (figure 3.6.3).  
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Therefore, in vitro, human recombinant topo II does not recognize specifically the lamin B2 
origin, but as part of a protein complex with other nuclear proteins is able to cleave the same sites on 




3.7 The effect of the histone deacetylase inhibitor trichostatin A on the topoisomerase I and II 
cleavages at the lamin B2 origin. 
 
Trichostatin A (TSA) is a histone deacetylase inhibitor which induces chromatin remodeling by 
raising the levels of histone acetylation. In HeLa cells treated with TSA the lamin B2 origin of DNA 
replication shows a relocalisation of start-sites of DNA synthesis (Kemp et al., 2005). Over a region of 
2kb the peak nascent DNA abundance is shifted from the usual position in order to give a dispersed 
region of initiation.  
Indeed HeLa cells treated for a short time with TSA show a reduced lamin B2 origin activity. 
Asynchronous growing HeLa cells were treated for 1-4h with 100ng/ml TSA, collected and 
resuspended in PBS with 10% glycerol and lysed in the wells of a 1.2% alkaline agarose gel. After an 
overnight run the short nascent DNA was isolated from the gel and competitive PCR analysis was 
performed in order to asses the abundance of origin (B48) and non-origin (B13) DNA fragments. The 
results are shown in figure 3.7.1. 
After one hour treatment with TSA the lamin B2 origin shows half of the nascent DNA 
enrichment compared to untreated controls. After four hours of TSA treatment the origin nascent DNA 
abundance is further reduced to a quarter of normal levels, with a B48:B13 ratio of roughly 2:1. This 
proves that even a short TSA incubation leads to the accumulation of acetylated histones and possibly 
other proteins with dramatic effects on origin function.  
This strong effect is accompanied by a disruption of the interaction of both topoisomerases I 
and II with the origin. Asynchronous growing HeLa cells were treated for 1-4h with TSA followed by 
treatment with either 1M CPT or 10nM VP16 in order to freeze, respectively, the topo I or topo II 
covalent complexes. The cells were then lysed, the DNA was isolated by proteinase K treatment, 
phenol/chloroform/isoamyl alcohol extraction and ethanol precipitation and the topo I or topo II 
cleavages were mapped by LM or TDPCR respectively. The results are illustrated in figure 3.7.2 for 







Figure 3.7.1 - Inhibition of the 
lamin B2 origin in the presence of the 
histone deacetylase inhibitor trichostatin 
A. The abundance of nascent DNA for 
origin (B48) and non-origin (B13) 
regions was measured by competitive 
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Figure 3.7.2 - Effect of trichostatin A on the interaction of 
topoisomerase I with the lamin B2 origin in vivo. G – In vitro DMS 
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Figure 3.7.3 - Effect of trichostatin A on the interaction of topoisomerase II with the lamin B2 
origin in vivo. Treatment of HeLa cells with TSA leads to the redistribution of the topo II cleavage sites 
at the origin (lanes 3,4 and 7,8) but not of the topo II cleavage site located far away from the origin 
(lanes 11,12). * - lower strand topo II cleavage site at the origin. ** - lower strand topo II cleavage site 
outside of the origin region. G – In vitro DMS treated genomic DNA. 
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Upon TSA treatment the topo I lower strand interaction with the origin is reduced as 
demonstrated by the faint LMPCR stop. However the topo II covalent complexes at the origin become 
relocated following TSA treatment. Both the upper and lower strand topo II cutting sites show a 
dispersed pattern of multiple cleavages over a large area. Furthermore, a comparison of the behavior of 
the origin and non-origin bound topo II molecules shows a distinct difference. If the origin cleavage 
sites show a dispersive pattern, the non-origin topo II cutting site is unaffected by the TSA treatment 
(the intensity of the TDPCR seems to become even stronger). This is yet further proof towards the idea 
that these two topo II molecules play very different roles on the DNA. 
Considering the strong effect of TSA on the topoisomerase II behavior at the origin, the in vitro 
origin complex assay was also performed in the presence of TSA. The Dignam nuclear extract, to 
which TSA was added up to a final concentration of 100ng/ml, was pre-incubated with 100-fold excess 
of competitor DNA for 20 minutes, then incubated for another 30 minutes with the origin fragment and 
topo II covalent complexes were stabilized by 
denaturation with SDS. The position of the topo II 
cleavages was mapped by hot extension and the results 
are shown in figure 3.7.4.  
In this case no difference in the topo II 
cleavage pattern could be detected, indicating that 
TSA does not interact directly with the topo II enzyme 







Figure 3.7.4 - Effect of trichostatin A on the 
interaction of topoisomerase II with the lamin B2 
origin in vitro. The addition of TSA to the in vitro 
complex formation reaction does not influence the 
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DNA topoisomerases are crucial enzymes for all living cells; they are the only proteins capable 
of modulating DNA topology in response to any DNA metabolical process. The wide range of effective 
anti-cancer agents which function by disrupting the catalytical cycle of topoisomerases is indicative of 
the uniqueness of these enzymes. It is not, thus, surprising that interfering with their biological action 
leads to cell death. Still, detailed information about their exact role, regulation and functional 
redundancy lacks in almost all model genetic systems. 
In humans there are six topoisomerase enzymes encoded in the nuclear genome, two type IB 
(topo I and topo Imt), two type II (topo II and topo II) and two type IA (topo III and topo III) 
proteins. Three of these enzymes, topo I, topo II and topo II, have been involved in a large number 
of studies as targets for anti-cancer drugs. However, most of these experiments have focused on 
acquiring knowledge about how to efficiently kill cancer cells, rather than on understanding why the 
topoisomerase-DNA covalent complexes are cytotoxic. A detailed characterization of the roles of 
topoisomerases inside the cell is needed in order to determine the most effective drug target. 
DNA replication in humans is a highly regulated and complex process, which involves the use 
of many apparently unrelated DNA sequences as origins of initiation of DNA replication. These 
sequences are chosen during the G1 phase of the cell cycle by the binding of pre-replicative complexes, 
which undergo dynamic reorganizations all through the length of G1. At the G1/S border, for all the 
sequences within the genome which will function as origins, a timing of replication initiation has 
already been assigned and only a subset of these (early origins) will fire immediately after entry into S 
phase. The rest (middle and late origins) will fire at different points in S phase in an orderly manner. 
The mechanism by which replication origins are chosen in the genome or the way in which it is 
established at which time point in S phase the origin will fire it is still not understood. 
In human cells, currently, there are very few origins well characterized and they show no 
sequence similarity between them. There seem to be many factors which influence the location and 
activity of the origin: the nuclear localization, an open chromatin structure, promoter regions for house-
keeping genes, the presence of binding sequences for specific protein factors, of bent DNA structures, 
of asymmetric AT-rich stretches (DePamphilis, 2006). Nevertheless there is no doubt that origins of 
DNA replication exist, they initiate DNA synthesis reproducibly from the same start-sites at every cell 
cycle, they function in different cell types and they also function when transferred to other genomic 
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loci, even in different organisms. The origin recognition complex (ORC), the structure which marks all 
replication origins and which is needed for the sequential assembly of the full pre-replicative complex, 
has no sequence specificity. In view of all these observations the question whether DNA topology is 
also a determining factor in the choice of sequences to be used as origins needs to be considered.  
In the present study the interaction of both human DNA topoisomerase I and II with the lamin 
B2 origin of DNA replication was investigated. The method applied to this purpose involved the use of 
two anti-cancer drugs, CPT and VP16, which are, respectively, enzyme-specific poisons for topo I and 
topo II. These drugs inhibit the religation step in the catalytic cycle of the enzymes leaving them 
covalently crosslinked to the DNA substrate. In this way the transient single (topo I) or double (topo II) 
stranded brakes introduced in the DNA are stabilized and can be mapped with the aid of LMPCR (topo 
I) or TDPCR (topo II). One important observation should be made regarding the mapping of the 
interaction of topoisomerase I and II with the origin, namely that the method used allows the detection 
of these enzymes only when they cleave the DNA. Should either topo I or topo II be present in the 
region analyzed without actively cleaving the DNA, they would be invisible in this study. However, 
lack of catalytical activity of either enzyme would point towards a structural role, most probably 
unrelated to topological regulation of the DNA. 
Treatment of asynchronous HeLa cells with the topo I poison CPT, revealed two single stranded 
cleavage sites, on the upper and lower strand respectively, well inside the origin region protected by the 
replicative complexes. These sites are located close and almost in a symmetrical manner with respect to 
the start-sites of DNA replication, on the templates for leading strand synthesis. Analysis of HeLa cells 
synchronized throughout the cell-cycle revealed that topo I interacts with both strands of the origin in 
M phase, very early G1 and late G1 towards the G1/S border. 
Unexpectedly treatment of asynchronous HeLa cells with VP16 also revealed two single 
stranded cuts, on the upper and lower strand respectively, close to the topo I sites but positioned closer 
to the start-site. These topo II cuts are also found inside the region protected by the replicative 
complexes, on the strands template for leading strand synthesis and are rather symmetrical with respect 
to the start-sites. However synchronization of HeLa cells showed that in contrast to topo I, topo II 
cleaves the origin only in M phase and in the middle of G1.  
This is not the first report of a topo II single stranded cut, in spite of the fact that the double 
stranded 4bp staggered cleavage is considered to be a hallmark of type II topoisomerases (Liu et al., 
1983, Muller et al., 1988 and Wong and Hsu, 1990). The reason for these in vivo single stranded breaks 
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is not obvious, nor is the existence of in vivo double stranded cleavages for the human enzyme. 
Remarkably, topo II can introduce the same single stranded cuts as part of an in vitro protein complex 
bound to origin DNA. These breaks are indeed due to topo II, as highlighted by the 
immunoprecipitation experiment both in vivo and in vitro. Furthermore, in vitro, the same cleavages 
can be stabilized by treatment with SDS or EDTA instead of VP16. This indicates that the single 
stranded nicks introduced by the enzyme are not conditioned by the anti-cancer drug used. 
Following the characterization of the interaction of the two topoisomerases with the origin 
(namely a region of 500bp) the surrounding area (500bp to the left and to the right) was also analyzed. 
For topo I no other cuts were observed with the exception of one cleavage positioned close to the 
TIMM13 promoter, a housekeeping gene located to the right with respect of the lamin B2 origin. 
Nevertheless this cleavage was observed only in S phase and may be related to the transcription of this 
gene. 
In the case of topo II just one other lower strand cleavage was observed, also single-stranded, in 
a region located over 200bp away and to the left of the origin. In contrast with the lower strand topo II 
cleavage close to the start-site, this particular cut is constant throughout the cell-cycle. There are three 
strong indications towards the idea that the origin and non-origin bound topo II molecules are part of 
different enzyme subsets and perform different actions on the DNA. First of all they behave differently 
throughout the cell cycle, they have different protein partners when bound to DNA (the origin topo II 
interacts with the hOrc2p in the middle of G1, while the non-origin bound topo II enzyme does not) 
and finally they show different sensitivity upon TSA treatment (the topo II origin cleavage becomes 
redistributed, while the one outside remains unaffected). 
Since topo II is a known member of the nuclear scaffold it is tempting to hypothesize that this 
cleavage far away from the origin might represent a scaffold attachment site. In the past many 
experiments aimed at mapping the position of scaffold attachment sites were based on drugs which 
specifically poisoned the topo II enzyme (Razin et al., 1991). Using this technique the lamin B2 origin 
itself was shown to be located close to a scaffold attachment region with a resolution of 2kb 
(Lagarkova et al., 1998). This theory would explain the behavior of this cleavage after TSA treatment: 
the nuclear scaffold is a structure insensitive to chromatin remodeling. Nevertheless further evidence is 
needed to substantiate this hypothesis.  
Previously, the positions of hOrc1p, hOrc2p and hCdc6p at the lamin B2 origin were mapped 
with nucleotide resolution for the M, middle of G1 and middle of S phases of the cell-cycle. Together 
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with the data obtained for topo I and topo II a new picture of the dynamic interaction of the origin 
binding proteins with the DNA emerges. Figure 4.1 illustrates the current knowledge of the protein-
DNA interactions at the human lamin B2 origin in different phases of the cell cycle. 
In mitosis the only proteins in contact with the origin are topo I and topo II as indicated by the 
lack of a DMS footprint in this area (Abdurashidova et al., 1998). Topoisomerase II is a known 
member of the protein scaffold of metaphase chromosomes and lack of both topo II and topo II 
isoforms in the cell severely impairs chromosome condensation and proper mitotic segregation (Gasser 
et al., 1986 and Sakaguchi and Kikuchi, 2004). This allows the speculation that topo II might be 
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Figure 4.1 - Summary of the mapped protein-DNA and protein-protein interactions at the lamin 
B2 origin of DNA replication. The position of Orc1p, Orc2p and Cdc6p on the lower strand was 
previously mapped (Abdurashidova et al., 2003). 
 
Topoisomerase I cleaves the origin DNA not only in M phase but also in the first half hour of 
G1. This piece of evidence would be in agreement with a possible role of topo I towards the end of 
mitosis, when it could contribute towards unpacking of chromosomes into their interphase relaxed 
state. Immediately entering G1 topo I might help with the first binding of the ORC to DNA. It is not 
known when the first binding of the origin recognition complex takes place at the lamin B2 origin. 
Interestingly, metazoan ORC has no sequence specificity but recent experiments in Drosophila 
melanogaster have showed that DmORC seems to prefer negatively supercoiled DNA (Remus et al., 
2004). If this were true also for hORC, then the presence of topo I might be connected with preparing 
the origin DNA for ORC binding. Furthermore considering that so far topoisomerase I is the only 
member of the replicative complexes which has a high affinity for the origin region in vitro, this 
enzyme might be itself a factor important for origin positioning. 
In the middle of G1 we find that topo II is again bound at the origin, on both the upper and 
lower strand, along with Orc2p, Orc1p and Cdc6p. The lower strand topo II molecule and Orc2p are 
interacting at the origin, which makes topo II an ORC protein partner in the middle of G1.  
As the cell enters the late G1 phase towards the G1/S border, topo II is no longer detectable in 
the origin area while the topo I enzyme has returned to this region. The exact position of Orc2 at this 
time is unknown but protein-protein cross-linking experiments have shown that topo I and Orc2 are 
interacting, making topo I an ORC protein partner at the origin, shortly before replicon initiation. 
In the middle of S phase, after the origin has fired, the only protein still in contact with the 
DNA is Orc2, its binding site shifted 17 nucleotides towards the start-sites. Finally, as the cell enters 
again M phase Orc2 disassociates from the origin and topo I and topo II come again in contact with this 
region.  
The nucleotide resolution mapping of the protein-DNA interactions at the lamin B2 origin has 
highlighted a dynamic competition between topo I, topo II and Orc2 proteins, throughout the cell cycle, 
for the same DNA binding sites. 
The Orc2 binding site in the middle of G1 overlaps with the lower strand topo I cleavage site 
(only 3 nucleotides difference). In good agreement with this observation topo I cannot be detected at 
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the origin at this point in the cell cycle. The S phase Orc2 binding site coincides with the lower strand 
topo II cleavage site (one nucleotide difference). Again no binding of topo II in the origin area is 
observed in this phase of the cell cycle. Furthermore, in mitosis when both topo I and topo II interact 
with the origin (but not with the same DNA molecule), ChIP analysis showed that Orc2 is not bound to 
the DNA (Abdurashidova et al., 2003). 
Therefore both topo I and topo II are not only protein partners for Orc2 at certain points during 
the cell cycle, but compete with this protein for the same binding sites. A possible explanation for this 
competition is the constant need for the modulation of origin DNA topology in order to maintain and/or 
strengthen the ORC-DNA binding. Another plausible hypothesis is that topo I and topo II are, together 
with ORC, part of a large multi-protein complex which is always in contact with the origin. 
Nevertheless the proteins which come into direct contact with the DNA change according to the needs 
of the DNA metabolism and cell cycle program.  
The proteins which address this specific topo I, topo II and ORC interaction with the origin are, 
most probably, still to be identified. Both ORC and topo II need to be directed to this region by other 
proteins, while the topo I affinity towards the origin area is, in all probability, not sufficient for 
dictating the behaviour of a replicative complex. Furthermore topo I is missing from the origin region 
for the most part of the G1 phase of the cell cycle.  
Topo I, however, seems to play a crucial role in replicon firing at the G1/S border. As shown in 
section 3.4, inhibition of the DNA relaxation activity of topo I by CPT treatment inhibits the initiation 
of DNA replication at the lamin B2 origin. This is a rather surprising result considering the generally 
accepted mechanism of CPT cytotoxicity: collision of a replication fork with a CPT stabilized topo I 
induced DNA break generates ‘replication run-off’, namely the formation of double-stranded breaks. If 
the CPT treatment occurs during S phase when DNA synthesis has already started then this outcome is 
likely. However if the cell is still in G1 when CPT is added do all origins still fire? Inhibition of at least 
a part of the origins of DNA replication would lead to a slower S phase, possibly an early mitosis when 
not all the DNA has been replicated yet and daughter cells with severe chromosome abnormalities.  
Unfortunately the role of topo II for origin activation is not easy to investigate. The topo II-
origin DNA interaction observed in the middle of G1 is too far time-wise from the initiation of DNA 
synthesis, an inhibition of the enzyme with VP16 for hours will activate a variety of checkpoint 
systems, making it impossible to distinguish between an inhibition of DNA synthesis as a primary or 
secondary effect of drug treatment. 
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The experiments involving the histone deacetylase inhibitor Trichostatin A do hint towards a 
correlation between topo II action and origin regulation. In asynchronous growing HeLa cells treatment 
with TSA leads to a redistribution of the origin topo II cleavages concurrent with a decrease in origin 
activity. However it is obvious from both in vivo and in vitro experimental data that origin bound topo 
II functions only as part of a complex with other proteins. Hence the topo II cleavage redistribution 
seen after TSA treatment is possibly connected to an accumulation of the acetylated form of members 
of the pre-replicative complex. This type of modification would probably lead to proteins losing their 
affinity for DNA and disassembly of the origin bound complex. 
Therefore both topoisomerase I and topoisomerase II are involved in origin regulation with 
topoisomerase I playing an essential role for the initiation of DNA replication. 
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5. CONCLUSIONS AND FUTURE DIRECTIONS 
 
 Both human topoisomerase I and topoisomerase II are new members of the lamin B2 origin pre-
replicative complex. Topoisomerase I introduces a single stranded cut in both origin upper and lower 
strand, positioned 42 and 27 nucleotides away from the start sites respectively, on the strands template 
for leading strand synthesis. These two cleavages are present at the origin in M phase, very early G1 
and late G1 towards the G1/S border. Topo I interacts with the human origin recognition complex via 
Orc2p immediately before origin activation and inhibition of its full catalytical activity at this moment 
of the cell cycle inhibits replicon initiation. In vitro human recombinant topo I shows a clear affinity for 
the lamin B2 origin by interacting with the same residues as in vivo on both the upper and lower strand. 
However the enzyme is able to cut 3 other sites on the upper strand and no consensus sequence was 
obtained by comparing all of the in vitro binding sites.   
Topoisomerase II also introduces a single stranded break in both the upper and lower strand of 
the origin DNA, positioned 19 and 11 nucleotides away from the start sites respectively, on the strands 
template for leading strand synthesis. These two cuts are present at the origin in M phase and middle of 
G1. Topo II is also a human origin recognition complex protein partner, via its interaction with hOrc2p, 
in the middle of G1. In vitro human recombinant topo II is unable to specifically recognise the origin 
DNA by itself, but as part of an in vitro origin specific protein complex it cleaves exactly the same sites 
as in vivo.  
Both topo I and topo II are competing in vivo with the Orc2p for the same binding sites. Topo I 
shares the Orc2 G1 binding site, while topo II the Orc2 S phase binding site. 
In the future the topoisomerase cell cycle specific interaction with the origin can be exploited in 
order to identify new members of the origin binding complex. Protein-protein crosslinking coupled 
with a topoisomerase block would enable the detection of other topoisomerase interactors on origin 
DNA. The in vitro origin specific protein complex can also be used for the same purpose. An added 
advantage of in vitro work is that of being able to identify new proteins by mass spectrometry. 
Considering the fact that topo II cannot recognise by itself the origin DNA, the protein partners which 
direct it at the origin could be determined. 
The question whether these two topoisomerases are interacting also with other origins of DNA 
replication should be taken into account. If that were the case, a new method for origin mapping might 
be established, based on cell cycle specific topo I-Orc2 and topo II-Orc2 interactions. Furthermore 
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considering the positions of the topo I and topo II cleavages with respect to the start-sites of DNA 
synthesis at the lamin B2 origin, the mapping of the start-sites for new origins would be reduced to the 
analysis of a 100bp region.  
The possible relationship of the lamin B2 origin with the nuclear scaffold can also be explored 
by studying the topo II cleavage site found 200bp away and to the left of the start-sites. This high-
resolution analysis of the topo II interaction with an origin and the surrounding region represents an 
unique opportunity for probing the hypothesis that origins of DNA replication represent scaffold 
anchoring sites, since, at present, topo II is considered the only ‘bona fide’ nuclear scaffold member. 
The data reported here concerning the effect of Trichostatin A on origin function can be used as 
a starting point for investigating the nucleosome position in this region and the connection between 
chromatin remodeling and origin position and function.  
Finally, the topoisomerase I site specific cleavages detected in vitro on a DNA fragment 
containing the origin can be developed into a topo I inhibitor or poison assay. The efficiency of new 
anti-cancer agents in freezing the topo I-DNA covalent complex or in inhibiting the DNA cleavages 
can be assessed in this manner. This method would be much more accurate that measuring the levels of 
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